



## Abstract Plenary

**Abstract Title:** Therapeutic vaccination for the elimination of HPV16+ high-grade dysplasia: A phase I clinical trial of the DNA vaccine pNGVL4aCRTE6E7L2, administered via the TriGrid™ Electroporation Device

**Abstract Plenary Presenter:** Kimberly Levinson, MD, MPH, MEd

**Date/Time:** 3/16/2024 between 6:45:00 AM and 7:45:00 AM

Special Interest Session - Cervical Cancer Eradication: It Takes a Village

**Abstract Title:** A feasibility study of upcycled smartphone-based colposcopy for visual inspection of cervix performed by community healthcare workers in rural Vietnam

**Abstract Plenary Presenter:** Ga Won Yim, MD, PhD

**Date/Time:** 3/16/2024 between 6:45:00 AM and 7:45:00 AM

Special Interest Session - Cervical Cancer Eradication: It Takes a Village

**Abstract Title:** Seeing health disparities in cervical cancer: Mapping behavioral and socioeconomic drivers of geographic dispersion of disease burden with the geo-analyzer tool

**Abstract Plenary Presenter:** Tara Castellano, MD

**Date/Time:** 3/16/2024 between 6:45:00 AM and 7:45:00 AM

Special Interest Session\* - Cervical Cancer Eradication: It Takes a Village

**Abstract Title:** Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab

plus concurrent chemoradiotherapy in patients with high-risk, locally-advanced cervical cancer

**Abstract Plenary Presenter:** Leslie M. Randall, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study

**Abstract Plenary Presenter:** Vicky Makker, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Pembrolizumab plus chemoradiotherapy for high-risk, locally-advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

**Abstract Plenary Presenter:** Linda R. Duska, MD, MPH

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in FRalpha positive, platinum-resistant ovarian cancer

**Abstract Plenary Presenter:** Gottfried E. Konecny, MD

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Efficacy and safety of alpelisib plus olaparib vs. chemotherapy in patients with platinum-resistant or refractory high-grade serous ovarian cancer without *BRCA* mutation: Primary analysis of the EPI

**Abstract Plenary Presenter:** Panagiotis A. Konstantinopoulos, MD, PhD

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone, or standard of care chemotherapy in platinum-resistant ovarian cancer (NRG-GY005)

**Abstract Plenary Presenter:** Jung-Min Lee, MD

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Interim post-progression data and updated survival in patients with newly-diagnosed advanced ovarian cancer in ATHENA-MONO

**Abstract Plenary Presenter:** Rebecca S. Kristeleit, MD, PhD

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Neoadjuvant tislelizumab plus chemotherapy in patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial

**Abstract Plenary Presenter:** Jindong Sheng

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial

**Abstract Plenary Presenter:** Yingjie Hu

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Effectiveness of 'survivors teaching students': A patient-centered experiential educational model of ovarian cancer for rising healthcare professionals

**Abstract Plenary Presenter:** Susan Leighton, MA

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Education Forum - Education Forum I: Patient Session

**Abstract Title:** Successful implementation of a 'goals-to-discharge' patient checklist following surgery for gynecologic cancer

**Abstract Plenary Presenter:** Maureen E. Byrne, MD, MSCR

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Education Forum - Education Forum I: Patient Session

**Abstract Title:** Sexual function and menopausal symptoms in patients at high risk of ovarian carcinoma undergoing interval salpingectomy or risk-reducing salpingo-oophorectomy in the prospective multicenter WISP trial

**Abstract Plenary Presenter:** Barbara M. Norquist, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Education Forum - Education Forum II: Premature Surgical Menopause: When Prevention Takes a Toll

**Abstract Title:** Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: A cost-effectiveness analysis

**Abstract Plenary Presenter:** Naomi N. Adjei, MD, MPH, MEd

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Education Forum - Education Forum II: Premature Surgical Menopause: When Prevention Takes a Toll

**Abstract Title:** Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer

**Abstract Plenary Presenter:** Jennifer G. Haag, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Ovarian cancer patients demonstrating durable clinical benefit from neoadjuvant chemo-immunotherapy are associated with significant reductions in tumor-infiltrating *CCR8*+ regulatory T cells

**Abstract Plenary Presenter:** Junsik Park, MD, PhD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Hidden threats: Chemotherapy-related clonal hematopoiesis in patients with ovarian cancer

**Abstract Plenary Presenter:** Sara Corvigno, MD, PhD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Spatial transcriptomics identifies unique loss of immunosurveillance in endometrial cancers of women with severe obesity

**Abstract Plenary Presenter:** Estefania Fernandez, MD, PhD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Repair assisted damage detection as a potential predictive biomarker for immunotherapy response in ovarian cancer

**Abstract Plenary Presenter:** Rodney P. Rocconi, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study

**Abstract Plenary Presenter:** Huijuan Yang

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

**Abstract Title:** Sacituzumab govitecan for Chinese patients with recurrent/metastatic cervical cancer: Interim analysis of the phase II basket study EVER-132-003

**Abstract Plenary Presenter:** Jusheng An

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

**Abstract Title:** A randomized controlled trial of wound infiltration with liposomal bupivacaine with or without intrathecal analgesia in patients undergoing laparotomy for advanced gynecologic malignancy

**Abstract Plenary Presenter:** Sean C. Dowdy, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Further analysis of the phase 3, single-dose, open-label study to investigate the efficacy of pafolacianine sodium injection for intraoperative imaging during cytoreductive surgery of folate receptor positive ovarian cancer

**Abstract Plenary Presenter:** Janos L. Tanyi, MD, PhD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Outcomes of low-volume metastatic disease in patients with early-stage squamous cell carcinoma undergoing sentinel lymph node biopsy: Results from the International Vulvar Cancer Consortium (IVUCCO)

**Abstract Plenary Presenter:** Dimitrios Nasioudis, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Overall survival following interval complete gross resection of advanced ovarian cancer via laparoscopy vs. open surgery: Analysis of the national cancer database

**Abstract Plenary Presenter:** Judy Hayek, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Mapping sentinel lymph nodes in early-stage ovarian cancer MELISA trial: A further step towards lymphadenectomy replacement?

**Abstract Plenary Presenter:** Nuria Agusti, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years

**Abstract Plenary Presenter:** Teresa K. Boitano, MD

**Date/Time:** 3/17/2024 between 9:00:00 AM and 9:45:00 AM

\* - Future of the Profession: Demonstrating Your Value and Negotiating for Needed Resources as a Gynecologic Oncologist

**Abstract Title:** Disease progression, survival, and molecular disparities in Black and white patients with endometrioid endometrial carcinoma in real world registries and legacy NRG Oncology phase III trials

**Abstract Plenary Presenter:** Zachary A. Kopelman, DO

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Education Forum - Education Forum V: Clinical Trials & Tribulations

**Abstract Title:** Disparities in NIH funding for cancer survivorship: A spotlight on breast and gynecologic cancers

**Abstract Plenary Presenter:** Payden White, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Education Forum - Education Forum V: Clinical Trials & Tribulations

**Abstract Title:** Artificial intelligence powered insights: Assessment of ChatGPT's treatment recommendations in gynecologic oncology

**Abstract Plenary Presenter:** Eric Rios-Doria, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Education Forum - Education Forum VI: AI, Robot: Oncologist vs. Chat GPT

**Abstract Title:** ChatGPT accurately performs genetic counseling for gynecologic cancers

**Abstract Plenary Presenter:** Jharna M. Patel, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Education Forum - Education Forum VI: AI, Robot: Oncologist vs. Chat GPT

**Abstract Title:** The prognostic value of circulating minimal residual disease in first-line treatment of ovarian cancer

**Abstract Plenary Presenter:** Tong Shu, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary IV: CtDNA: Molecular Mirrors & Markers

**Abstract Title:** Early detection of uterine corpus endometrial carcinoma utilizing plasma cfDNA fragmentomics

**Abstract Plenary Presenter:** Qin Xu

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary IV: CtDNA: Molecular Mirrors & Markers

**Abstract Title:** Circulating tumor-specific HPV DNA is a sensitive and specific biomarker for the surveillance of invasive cervical carcinoma

**Abstract Plenary Presenter:** Elena Pereira, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM



Focused Plenary - Focused Plenary IV: CtDNA: Molecular Mirrors & Markers

**Abstract Title:** Monitoring minimal residual disease using circulating tumor DNA in patients treated long-term with PARP inhibitors for ovarian cancer

**Abstract Plenary Presenter:** Dahye Lee, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary IV: CtDNA: Molecular Mirrors & Markers

**Abstract Title:** Utility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies

**Abstract Plenary Presenter:** Mihal Shalamov, BS, MS

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary IV: CtDNA: Molecular Mirrors & Markers

**Abstract Title:** Gamma secretase inhibitors in combination with cytotoxic agents decrease migration and invasion uterine leiomyosarcoma

**Abstract Plenary Presenter:** Yasmin Abedin, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Capitalizing on absence of *TP53* mutations in low-grade serous and clear cell ovarian cancer with XPO1 inhibition

**Abstract Plenary Presenter:** Dimitrios Nasioudis, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** *TP53* and *KRAS* somatic mutations are associated with worse outcomes in stage I mucinous ovarian carcinomas

**Abstract Plenary Presenter:** Yingao Zhang, MD, MS

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Preclinical efficacy of of RAF/MEK clamp avutometinib in combination with FAK inhibition for low grade serous ovarian cancer

**Abstract Plenary Presenter:** Michelle Greenman, MD, MPH

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Efficacy of sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial

**Abstract Plenary Presenter:** Qinglei Gao

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Compare the outcomes between open and minimally invasive surgery surgery procedures in primary malignant melanoma of the vagina and cervix

**Abstract Plenary Presenter:** Cuibo Lin, MD, MBA, MS

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Response to treatment with nab-Sirolimus in patients with perivascular epithelioid cell sarcoma of gynecologic or peritoneal origin: Subgroup analysis from AMPECT

**Abstract Plenary Presenter:** Thomas J. Herzog, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary V: Rare Care: Updates in Uncommon Cancers

**Abstract Title:** Progression-free and overall survival in newly diagnosed homologous recombination DNA-repair deficient ovarian cancer without a *BRCA* mutation

**Abstract Plenary Presenter:** Stephen Graves, MD, MBA, MS

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** Mainstreaming in gynecologic oncology clinics triples the odds of genetic testing in patients with epithelial ovarian cancer

**Abstract Plenary Presenter:** Tiffany Y. Sia, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** Increase in counseling seen among patients at risk for genetic cancer syndromes with use of a digital risk stratification tool in a historically underserved population: A randomized controlled trial

**Abstract Plenary Presenter:** Emily M. Webster, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** Finding the needle in the haystack: Identifying risk of MDS/AML after PARP inhibitor treatment

**Abstract Plenary Presenter:** Amma Asare, MD, PhD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** STIC to it: The incidental finding of serous tubal intraepithelial carcinoma requires further testing

**Abstract Plenary Presenter:** Sha Sha, MD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** Population-based *BRCA1* and *BRCA2* genetic testing is cost-effective in Canada

**Abstract Plenary Presenter:** Caitlin Fierheller, PhD

**Date/Time:** 3/17/2024 between 1:45:00 PM and 2:45:00 PM

Focused Plenary - Focused Plenary VI: STICS and Stones and Genetic Overtones

**Abstract Title:** The impact of financial hardship on symptoms and quality of life in recurrent ovarian cancer

**Abstract Plenary Presenter:** Heidi S. Donovan, PhD, RN

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Disparities in contemporary human papillomavirus (HPV) vaccination uptake: An all of us research program study

**Abstract Plenary Presenter:** Terrence Y. Wong, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Uterine cancer among Asian Americans: Disparities and clinical characteristics and disease presentations

**Abstract Plenary Presenter:** Michael T. Richardson, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Gardasil at the time of abortion visit: A quality improvement initiative

**Abstract Plenary Presenter:** Catherine E. Hermann, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Cost effectiveness analysis of immunotherapy regimens in advanced or recurrent endometrial cancer: An analysis of the NRG-GY018 and RUBY trials

**Abstract Plenary Presenter:** Alex Francoeur, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Survival disparities in Black patients compared to white patients enrolled in Gynecologic Oncology Group randomized clinical trials: An analysis of 1882 women

**Abstract Plenary Presenter:** Caitlin Johnson, MPH

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Financial toxicity in gynecologic oncology and its impact on medication access, debt, and food insecurity

**Abstract Plenary Presenter:** Alana Lanser

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary IX: Healthcare Disparities: Drivers and Determinants

**Abstract Title:** Pixel pioneers: A novel artificial intelligence modeling tool for laparoscopic assessment of ovarian carcinoma

**Abstract Plenary Presenter:** Amma Asare, MD, PhD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VII: Surgical Video: Behind the Double Doors

**Abstract Title:** Personalized ablative therapy for oligometastatic cervical cancer (OMCC): Unexplored potential

**Abstract Plenary Presenter:** Christopher A. Walker, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VIII: Advances in Radiation Techniques Beam Me Up Scotty (Not Your Parents Rads)

**Abstract Title:** Hypofractionated short course radiation therapy for recurrent ovarian cancer: Retrospective cohort study

**Abstract Plenary Presenter:** Emily A. Miller, MD, MPH

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VIII: Advances in Radiation Techniques Beam Me Up Scotty (Not Your Parents Rads)

**Abstract Title:** Prediction of radiation proctitis in cervical cancer radiotherapy using MRI-based radiomics

**Abstract Plenary Presenter:** Sufang Deng

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VIII: Advances in Radiation Techniques Beam Me Up Scotty (Not Your Parents Rads)



## Featured Posters

**Abstract Title:** Methodologies for the disaggregation of Asian racial and ethnic subgroups to determine trends in ovarian cancer

**Featured Poster Presenter:** Sarah S. Lee, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Early-phase vs. late-phase clinical trials: Trends in enrollment of racial and ethnic minority groups

**Featured Poster Presenter:** Michael T. Richardson, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Research funding disparity in uterine cancer: An analysis of funding and race in relation to burden of disease

**Featured Poster Presenter:** Arielle Katcher, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Tracking the relationship between accrual and comorbidities in clinical trial enrollment (TRACE)

**Featured Poster Presenter:** Ann Oluloro, MD, MPH

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Risk of cancer progression of non-atypical endometrial hyperplasia in a diverse patient population: A long-term, follow-up study

**Featured Poster Presenter:** Benjamin Yao, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Risk of endometrial carcinoma in patients with atypical endometrial hyperplasia in a population of predominantly racial and ethnic minorities: A single institution study

**Featured Poster Presenter:** Jenny L. Soiffer, MD, MPH

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Racial and ethnic inequities in end-of-life care intensity among patients with gynecologic cancers in California

**Featured Poster Presenter:** Daisy A. Cruz, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Endometrial pathology in premenopausal patients seeking emergency care for abnormal uterine bleeding: High risk of endometrial malignancy and premalignancy

**Featured Poster Presenter:** Jessica Grubman, MD, MAS

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM



Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Increase in uterine cancer incidence among Black patients in the United States: A United States cancer statistics study of nearly 95,000 patients from 2001-2019

**Featured Poster Presenter:** Vignesh Ramchandran, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session I: Disaggregated Data to Dismantle Disparities

**Abstract Title:** Phase II of weekly paclitaxel, lenvatinib, and pembrolizumab in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer

**Featured Poster Presenter:** Floor J. Backes, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

**Featured Poster Presenter:** Nicoletta Colombo, MD, PhD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Evaluating differences among PRAPARE screening assessments of gynecologic oncology patients based on socio-demographic factors

**Featured Poster Presenter:** Tavonna D. Kako, MD, MS

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** A pilot randomized controlled trial of BOLSTER: A nurse-led telehealth intervention for patients with peritoneal carcinomatosis and their caregivers

**Featured Poster Presenter:** Rachel A. Pozzar, PhD, RN

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Fuzuloparib as maintenance therapy in patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial

**Featured Poster Presenter:** Lingying Wu, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer

**Featured Poster Presenter:** Paulina J. Haight, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Post-operative complications in elderly patients undergoing surgery for ovarian cancer: A NSQIP analysis

**Featured Poster Presenter:** Lina Salman, MD, MSc

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** The molecular classification in endometrial cancer applied to endometrial biopsy: A prospective preliminary data of endometrial biopsy and a proposal for pre-operative surgery planning in the era of precision medicine

**Featured Poster Presenter:** Giulia Spagnol, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010)

**Featured Poster Presenter:** Wenjun Cheng, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Defying platinum resistance: Boosting overall survival in platinum-resistant ovarian cancer patients

**Featured Poster Presenter:** Kyle C. Chesler, BS

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** Fertility outcomes in patients undergoing fertility-sparing treatment of atypical hyperplasia and grade one cancer of the endometrium using progestin therapy: Results of a novel, specialized oncofertility program

**Featured Poster Presenter:** Oleksandra Dzyubak, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session II: Together We Tackle Cancer

**Abstract Title:** A functional homologous recombination deficiency and replication stress assay predict response to platinum chemotherapy in high-grade serous ovarian cancer

**Featured Poster Presenter:** Amanda Compadre, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** HER-2 status among a cohort of endometrial cancer patients

**Featured Poster Presenter:** Kari E. Hacker, MD, PhD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Folate receptor positivity in low-grade serous ovarian cancer: Exploring new therapeutic possibilities

**Featured Poster Presenter:** Beryl L. Manning-Geist, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Mapping shared neoantigens and T cell dysregulation in MSI-H endometrial cancer patients

**Featured Poster Presenter:** Sharonne Holtzman, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** A spatial proteomic study of platinum refractory HGSOc implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment

**Featured Poster Presenter:** Kaitlyn Kincaid, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Predicting clinical trial availability in gynecological oncology [PENTAGON]

**Featured Poster Presenter:** Amelia M. Jernigan, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer

**Featured Poster Presenter:** Mary Kathryn Abel, MD, MS

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Geospatial disparities in access to fertility preservation for women with early-stage gynecologic cancers and breast cancer

**Featured Poster Presenter:** Alexa N. Kanbergs, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Hormonal therapy in low-grade endometrial stromal sarcoma: What is the current standard of care?

**Featured Poster Presenter:** Reem Saab, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Featured Poster Session - Rapid-Fire Featured Poster Session III: Discovery to Delivery

**Abstract Title:** Improving quality of life using patient reported outcome measures post-operatively via text messaging: A randomized control trial (PROMPT study)

**Featured Poster Presenter:** Alli M. Straubhar, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** Developing ovarian cancer innovative diversion criteria to decrease the rate of diverting ileostomy in patients undergoing cytoreductive surgery for gynecologic malignancy

**Featured Poster Presenter:** Taymaa May, MD, MS, FRCSC

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** A predictive nomogram for endometrial cancer based on pre-operative assessment in patients with endometrial intraepithelial neoplasia

**Featured Poster Presenter:** Michelle Ertel, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** Setting the standard for postoperative venous thromboembolism prophylaxis in gynecologic cancer patients: Apixaban showed similar outcomes with lower cost compared to enoxaparin

**Featured Poster Presenter:** Anne Knisely, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** Age, comorbidities, and cancer: Their associations with memory impairment in postmenopausal gynecologic cancer survivors in the women's health initiative

**Featured Poster Presenter:** Benjamin Matthews, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** Engaging endometrial cancer survivors as peer supporters for equitable cancer care: The SISTER study training process

**Featured Poster Presenter:** Adrienne Moore

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** Exploring the preferences and experiences of female cancer survivors regarding fertility and fertility preservation: Insights from the survivorship oncofertility barriers survey

**Featured Poster Presenter:** Alexa N. Kanbergs, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship

**Abstract Title:** HIPEC is associated with improved overall survival in advanced-stage ovarian cancer patients undergoing interval cytoreductive surgery: A national cancer database analysis

**Featured Poster Presenter:** Adrian Y. Kohut, MD

**Date/Time:** 3/18/2024 between 9:30:00 AM and 10:30:00 AM

Featured Poster Session - Rapid-Fire Featured Poster Session IV: Optimizing Surgery, Recovery, and Survivorship



## Late-Breaking Abstracts

**Abstract Title:** Overall survival and progression-free survival by PD-L1 status in endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

**Late-Breaking Abstract Presenter:** Ramez N. Eskander, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Raludotatug deruxtecan monotherapy in patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human, phase I study

**Late-Breaking Abstract Presenter:** Kathleen N. Moore, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Overall survival in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY

**Late-Breaking Abstract Presenter:** Matthew A. Powell, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer (inovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study



**Late-Breaking Abstract Presenter:** Brian M. Slomovitz, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy in patients with primary-advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

**Late-Breaking Abstract Presenter:** Mansoor R. Mirza, MD

**Date/Time:** 3/16/2024 between 8:30:00 AM and 9:45:00 AM

Scientific Plenary - Scientific Plenary I: News We Can All Use

**Abstract Title:** Survival of patients with early-stage cervical cancer after SLN biopsy without systematic pelvic lymphadenectomy: Primary endpoint outcome of the SENTIX prospective, single-arm, international trial (CEEGOG CX-01; ENGOT-CX2)

**Late-Breaking Abstract Presenter:** David Cibula, MD

**Date/Time:** 3/16/2024 between 10:45:00 AM and 12:00:00 PM

Scientific Plenary - Scientific Plenary II: Moving the Needle Together

**Abstract Title:** Molecular markers of response to enzalutamide-based therapy in advanced or recurrent endometrioid endometrial adenocarcinoma (ENPAC Study)

**Late-Breaking Abstract Presenter:** Anil K. Sood, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** Prognostic implications of minimal residual disease detection by second-look laparoscopy and circulating tumor DNA in patients with ovarian cancer after frontline therapy

**Late-Breaking Abstract Presenter:** Anne Knisely, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary I: The Science to Drive Purpose

**Abstract Title:** A randomized, phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally-advanced cervical cancer: The GCIG INTERLACE Trial

**Late-Breaking Abstract Presenter:** Jonathan Ledermann, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

**Abstract Title:** BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030): A randomized, phase III trial of first-line atezolizumab with bevacizumab and platinum-based chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer

**Late-Breaking Abstract Presenter:** Ana Oaknin, MD, PhD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

**Abstract Title:** Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

**Late-Breaking Abstract Presenter:** Xiaohua Wu, MD

**Date/Time:** 3/16/2024 between 2:15:00 PM and 3:30:00 PM

Focused Plenary - Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

**Abstract Title:** Evaluation of physical function and quality of life before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (GOG-278)

**Late-Breaking Abstract Presenter:** Allan L. Covens, MD, FRCSC

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** Evaluation efficacy and fertility after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (GOG-278) funded by NCI/NCORP (NCT01649089)

**Late-Breaking Abstract Presenter:** Allan L. Covens, MD, FRCSC

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** Clinical activity of tazemetostat, an *EZH2* inhibitor, in patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without *ARID1A* mutations (NRG-GY014)

**Late-Breaking Abstract Presenter:** Ramez N. Eskander, MD

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer

**Late-Breaking Abstract Presenter:** Debra L. Richardson, MD

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** Avutometinib plus defactinib in recurrent, low-grade serous ovarian cancer: A subgroup analysis of ENGOT-ov60/GOG-3052/RAMP 201 Part A

**Late-Breaking Abstract Presenter:** Susana N. Banerjee, MBBS, MA, PhD, FRCP

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** Refining ovarian cancer test accuracy scores: A multicentre, prospective, cohort study investigating diagnostic accuracy in women with symptoms of suspected ovarian cancer (The ROCKeTS Study): Results for post-menopausal women

**Late-Breaking Abstract Presenter:** Sudha Sundar, MBBS, MPhil, MRCOG

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** APL-1702 long-term efficacy and safety for cervical histologic, high-grade squamous intraepithelial lesions: Results from a randomized, phase III, global study

**Late-Breaking Abstract Presenter:** Fei Chen

**Date/Time:** 3/17/2024 between 4:15:00 PM and 5:30:00 PM

Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1

**Abstract Title:** Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status

**Late-Breaking Abstract Presenter:** Hye Sook Chon, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

**Late-Breaking Abstract Presenter:** Bradley R. Corr, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Overall survival in patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: Ancillary analysis of GOG-0258

**Late-Breaking Abstract Presenter:** Aine E. Clements, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance in patients with newly-diagnosed, advanced ovarian cancer without a tumor *BRCA1/BRCA2* mutation: Updated results from DUO-O/ENGOT-ov46/GOG-3025

**Late-Breaking Abstract Presenter:** Philipp Harter, MD, PhD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study

**Late-Breaking Abstract Presenter:** Christian Marth, MD, PhD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a *TP53 Y220C* mutation

**Late-Breaking Abstract Presenter:** Alison Schram, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer: Overall survival and additional secondary efficacy endpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOTEN10 Trial

**Late-Breaking Abstract Presenter:** Jean-François Baurain, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

**Abstract Title:** Niraparib maintenance therapy using an individualized starting dose in patients with platinum-sensitive, recurrent ovarian cancer (NORA Trial): Final overall survival analysis of a randomized, double-blind, placebo-controlled, phase III trial

**Late-Breaking Abstract Presenter:** Xiaohua Wu, MD

**Date/Time:** 3/18/2024 between 2:30:00 PM and 3:45:00 PM

Scientific Plenary - Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out



## Poster Presentations

**Abstract Title:** Comprehensive genomic profiling in ovarian cancer histotypes: Biomarker prevalence and real-world prognosis

**Poster Presenter:** Venkatesh Krishnan, PhD

*Accepted as Poster Session I*

**Abstract Title:** Cervical cancer disparities in Puerto Rico: Does BMI associate with cervical dysplasia regardless of HPV genotypes?

**Poster Presenter:** Ana L. Rosario Santos, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Trends in the management of early-stage cervical cancer: An analysis of the National Cancer Database

**Poster Presenter:** Jennifer Wolf, MD

*Accepted as Poster Session I*

**Abstract Title:** LCI139: In silico design of a novel multitarget small molecular inhibitor for the treatment of PTEN mutant endometrial adenocarcinoma

**Poster Presenter:** Vaidehi Mujumdar, MD

*Accepted as Poster Session I*

**Abstract Title:** First-degree family history of cancer in women with stage I endometrial carcinoma: Prevalence and prognostic impact

**Poster Presenter:** Abdelrahman Yousif, MD

*Accepted as Poster Session I*

**Abstract Title:** The impact of enhanced recovery after surgery on postoperative outcomes in gynecologic oncology hysterectomies: A community hospital perspective

**Poster Presenter:** Rachel Levine, DO

*Accepted as Poster Session I*

**Abstract Title:** Survival analysis of a prospective intraoperative algorithm to guide surgical staging in early-stage endometrial cancer

**Poster Presenter:** David Schweer, MD

*Accepted as Poster Session I*

**Abstract Title:** PDE1A in epithelial ovarian cancer: Oncogenic role, metastatic association, and potential as a prognostic biomarker and therapeutic target

**Poster Presenter:** Gwan Hee Han, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Identification and evaluation of UR238, a first-in-field small molecule inhibitor of HE4, in a syngeneic rat ovarian cancer model

**Poster Presenter:** Cameron W.A. Snyder, AS

*Accepted as Poster Session I*

**Abstract Title:** Racial and ethnic disparities in disease progression and subsequent survival among patients with ovarian cancer in the Kaiser Permanente Research on Ovarian Cancer Survival study

**Poster Presenter:** Juraj Kavecansky, MD

*Accepted as Poster Session I*

**Abstract Title:** Uterine manipulation during minimally invasive surgery for early-stage endometrial cancer (MAN-U Trial)



**Poster Presenter:** Anthony B. Costales, MD

*Accepted as Poster Session I*

**Abstract Title:** Antihyperglycemic medication may alter early endometrioid endometrial cancer outcomes

**Poster Presenter:** Corrine A. Nief, PhD

*Accepted as Poster Session I*

**Abstract Title:** Rising rates of advanced uterine cancer in minority populations: A United States cancer statistics study of 75,000 patients

**Poster Presenter:** Alex A. Francoeur, MD

*Accepted as Poster Session I*

**Abstract Title:** Investigating the role of human epididymis protein 4 (HE4)-mediated immunosuppression in ovarian cancer

**Poster Presenter:** John P. Miller, MS

*Accepted as Poster Session I*

**Abstract Title:** Comprehensive serum glycopeptide spectra analysis combined with traditional markers for early-stage epithelial ovarian cancer identification

**Poster Presenter:** Mikio Mikami, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Changes in HRD status during treatment for ovarian high-grade serous carcinoma

**Poster Presenter:** Noriomi Matsumura, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** CDK4/6 inhibitors potently inhibit cell viability in pre-clinical models of adult-type ovarian granulosa cell tumors

**Poster Presenter:** Allison L. Brodsky, MD

*Accepted as Poster Session I*

**Abstract Title:** Single-cell RNA sequencing reveals S100A9+ tumor subtype as a metastatic regulator of high-grade serous carcinoma

**Poster Presenter:** Junfen Xu, MD

*Accepted as Poster Session I*

**Abstract Title:** Oncologic outcomes of minimally invasive surgery versus laparotomy for the treatment of FIGO 2009 stage II endometrial cancer

**Poster Presenter:** Christian Dagher, MD

*Accepted as Poster Session I*

**Abstract Title:** Characteristics of mismatch repair deficient endometrial cancer in a diverse cohort

**Poster Presenter:** Sara Brenner, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management

**Poster Presenter:** Andrea M. Neilson, MD, FRCS(C)

*Accepted as Poster Session I*

**Abstract Title:** Up-front tumor next-generation sequencing for diagnosis of Lynch syndrome in endometrial cancer

**Poster Presenter:** Oleksandra Dzyubak, MD

*Accepted as Poster Session I*

**Abstract Title:** Gynecologic cancers among American Indian and Alaska Native women living in the upper midwest

**Poster Presenter:** Keely K. Ulmer, MD

*Accepted as Poster Session I*

**Abstract Title:** Association of high-grade serous ovarian cancer sample clonality with clinical outcomes

**Poster Presenter:** Keely K. Ulmer, MD

*Accepted as Poster Session I*

**Abstract Title:** Prediction of clinical outcomes in ovarian outcomes using genomic variation

**Poster Presenter:** Katharine Linder, MD

*Accepted as Poster Session I*

**Abstract Title:** A more accurate measure of endometrial cancer incidence rates in New Mexico: A hysterectomy-corrected analysis

**Poster Presenter:** Ashlee Candelaria, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Geographic and racial disparities in receipt of low-quality surgical care among patients with non-metastatic uterine cancer

**Poster Presenter:** Benjamin B. Albright, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** Genomic characterization of mucinous adenocarcinoma of the cervix

**Poster Presenter:** Susan Duyar-Ayerdi, MD, MA

*Accepted as Poster Session I*

**Abstract Title:** Patterns of recurrence and outcomes in vulvar extramammary Paget's disease

**Poster Presenter:** Clarissa Lam, MD

*Accepted as Poster Session I*

**Abstract Title:** Deciphering the role of cancer-associated fibroblasts in ovarian cancer: a Mendelian randomisation-based study of potential drug target genes

**Poster Presenter:** Bo Ding

*Accepted as Poster Session I*

**Abstract Title:** Testing for FRalpha in ovarian cancer: Why testing the primary matters more than the metastasis

**Poster Presenter:** Rebecca A. Previs, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** Spatial RNA sequencing supports programmed death ligand 2 as a potential immunotherapy target in high-grade serous ovarian carcinoma

**Poster Presenter:** Elise Yates, MD

*Accepted as Poster Session I*

**Abstract Title:** One stop colon and endometrial screening (OnCE): A prospective study of combined cancer screening for Lynch syndrome

**Poster Presenter:** Emily A. Miller, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Surfing for answers: Evaluating the quality of online health information for hereditary breast and ovarian cancer syndromes

**Poster Presenter:** Jesse T. Brewer, BA

*Accepted as Poster Session I*

**Abstract Title:** Perioperative outcomes in gynecologic pelvic exenterations before and after enhanced recovery after surgery implementation

**Poster Presenter:** Sarah P. Huepenbecker, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Shifting trends and sicker patients: Reassessing benign hysterectomies performed by gynecologic oncologists

**Poster Presenter:** Olivia W. Foley, MD

*Accepted as Poster Session I*

**Abstract Title:** Homologous recombination status in BRCA wild type patients as a predictor of disease volume and surgical outcome in patients with high-grade serous ovarian cancer

**Poster Presenter:** Liat Hogen, MD

*Accepted as Poster Session I*

**Abstract Title:** An educational video's impact on knowledge of cervical cancer prevention and screening among Hispanic patients

**Poster Presenter:** Stephanie M. Wang, MD

*Accepted as Poster Session I*

**Abstract Title:** Variability of folate receptor alpha expression by race in recurrent ovarian cancer patients

**Poster Presenter:** Sarah S. Lee, MD

*Accepted as Poster Session I*

**Abstract Title:** Aberrant expression of progesterone receptor isoforms in endometrial hyperplasia and endometrial cancer

**Poster Presenter:** Kieran Seay, MD, PHD

*Accepted as Poster Session I*

**Abstract Title:** The impact of race, ethnicity, and socioeconomic status on fertility-sparing management of early-stage cervical cancer

**Poster Presenter:** Matthew L. Flint, MD

*Accepted as Poster Session I*

**Abstract Title:** HRD and other targetable mutations in ovarian cancer: The importance of tumor site of origin and cell type

**Poster Presenter:** Chinmayi Aryasomayajula, MD

*Accepted as Poster Session I*

**Abstract Title:** RAS/RAF/MEKmutated high-grade serous ovarian cancer susceptible to Raf inhibition in vitro but not in vivo

**Poster Presenter:** Ioana L. Bondre, MD

*Accepted as Poster Session I*

**Abstract Title:** Elevated integrin subunit and beta-3 in recurrent compared to newly diagnosed ovarian cancer patient ascites: A promising new target to prevent recurrence

**Poster Presenter:** Jacqueline A. Bohn, MD

*Accepted as Poster Session I*

**Abstract Title:** Overall survival and mutational landscape comparison between Appalachian and non-Appalachian patients with ovarian cancer: An Oncology Research Information Network analysis

**Poster Presenter:** Allison L. Swiecki-Sikora, MD

*Accepted as Poster Session I*

**Abstract Title:** Factors influencing gynecologic risk reduction surgeries for *BRCA1* or *BRCA2* germline mutation carriers

**Poster Presenter:** Andrea R. Hagemann, MD, MSci

*Accepted as Poster Session I*

**Abstract Title:** Development and validation of MRI-based machine learning models for predicting lymph node metastasis in cervical cancer

**Poster Presenter:** Qin Xu

*Accepted as Poster Session I*

**Abstract Title:** ESR1 alterations in gynecologic cancers

**Poster Presenter:** Aysegul Balyimez, PhD

*Accepted as Poster Session I*

**Abstract Title:** Germline testing among ovarian cancer patients using an integrated clinical pathway dashboard at Kaiser Permanente, Northern California

**Poster Presenter:** Ali Duffens, MD

*Accepted as Poster Session I*

**Abstract Title:** A new standard for surgical site infection prevention in gynecologic cancer: Metronidazole plus cefazolin better than cefazolin alone

**Poster Presenter:** Anne Knisely, MD

*Accepted as Poster Session I*

**Abstract Title:** Analyzing time to treatment for persons newly diagnosed with endometrial cancer in the United States: Exploring racial/ethnic and urban/rural disparities

**Poster Presenter:** Tara Castellano, MD

*Accepted as Poster Session I*

**Abstract Title:** Cisplatin encapsulated human macrophage-engineered vesicles for utilization in ovarian cancer treatment

**Poster Presenter:** David Schweer, MD

*Accepted as Poster Session I*

**Abstract Title:** Restaging endometrial cancer patients according to the 2023 FIGO Guidelines demonstrates no difference in survival by stage: a large, retrospective cohort validated by the TCGA dataset

**Poster Presenter:** Rosemary N. Senguttuvan, MD

*Accepted as Poster Session I*

**Abstract Title:** Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer

**Poster Presenter:** Rachel Watson, MD

*Accepted as Poster Session I*

**Abstract Title:** RAD52 is a potential therapeutic target in PARP inhibitor resistant BRCA-deficient ovarian cancer

**Poster Presenter:** Yukihide Ota, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Predictors of operative time for ovarian cancer debulking surgery

**Poster Presenter:** Donya Derakshani, BS

*Accepted as Poster Session I*

**Abstract Title:** The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer

**Poster Presenter:** Dongling Zou, PhD

*Accepted as Poster Session I*

**Abstract Title:** AI machine learning survival models for the prediction of epithelial ovarian cancer outcomes

**Poster Presenter:** John Nakayama, MD

*Accepted as Poster Session I*

**Abstract Title:** AI-assisted classification of epithelial ovarian cancer patients using machine learning clustering to determine the rate of platinum sensitivity and disease recurrence

**Poster Presenter:** John Nakayama, MD

*Accepted as Poster Session I*



**Abstract Title:** Endometrial cancer tumor genetic testing practice patterns among gynecologic oncologists

**Poster Presenter:** Joseph A. DeMari, MD

*Accepted as Poster Session I*

**Abstract Title:** Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

**Poster Presenter:** Premal H. Thaker, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** Evaluating the risks of pleural effusions and chest tube placement at the time of cytoreductive surgery for advanced ovarian cancer

**Poster Presenter:** Ryan M. Kahn, MD, MHS

*Accepted as Poster Session I*

**Abstract Title:** Intraperitoneal therapy with engineered Newcastle disease virus encoding interleukin-12 in combination with PD-1 blockade for ovarian cancer

**Poster Presenter:** Ryan M. Kahn, MD, MHS

*Accepted as Poster Session I*

**Abstract Title:** Recruitment of patients of color in gynecology oncology clinical trials

**Poster Presenter:** Dagny Ochoa Maravilla, BA

*Accepted as Poster Session I*

**Abstract Title:** Molecular correlates of response to immunotherapy in advanced or recurrent endometrial cancer: A pilot study

**Poster Presenter:** Ayesha Kar, MD

*Accepted as Poster Session I*

**Abstract Title:** Whole-genome sequencing-based genomic characterization of uterine serous carcinoma

**Poster Presenter:** Sarah Andres, DO

*Accepted as Poster Session I*

**Abstract Title:** Defects in mismatch repair promote disease character likeness amongst Black and white women with endometrial cancer

**Poster Presenter:** Dana Lewis, DO

*Accepted as Poster Session I*

**Abstract Title:** Molecular subtypes and genomic landscape of undifferentiated and dedifferentiated endometrial cancer

**Poster Presenter:** Christian Dagher, MD

*Accepted as Poster Session I*

**Abstract Title:** Molecular characterization of squamous cell ovarian cancers for identification of therapeutic targets

**Poster Presenter:** Jessie Hollingsworth, MD

*Accepted as Poster Session I*

**Abstract Title:** Oncologic and surgical outcomes of robotic-assisted versus conventional laparoscopy for the treatment of clinically uterine-confined high-grade endometrial carcinoma

**Poster Presenter:** Christian Dagher, MD

*Accepted as Poster Session I*

**Abstract Title:** Understanding real-world treatment patterns of patients with advanced ovarian cancer in the first-line maintenance setting: the FIRST STEP study

**Poster Presenter:** Linda Kalilani, PhD, MSc

*Accepted as Poster Session I*

**Abstract Title:** Supervised machine learning with a novel set of 20 genes predicts likelihood of early or late recurrence of high-grade serous ovarian cancer

**Poster Presenter:** Radhika P. Gogoi, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Significant age cut-off of 73 years for advanced ovarian serous cystadenocarcinoma patients: Insights from real-world study

**Poster Presenter:** Ke Zhang

*Accepted as Poster Session I*

**Abstract Title:** HIF2A shows potential tumor promoting effect and could be poor prognostic factor in ovarian clear cell carcinoma

**Poster Presenter:** Ken Yamaguchi, MD, PHD

*Accepted as Poster Session I*

**Abstract Title:** Immunohistochemical expression of ER, TP53 and HER-2 as predictive biomarkers of immunotherapy in endometrial cancer

**Poster Presenter:** Aristeia Maria Papanota

*Accepted as Poster Session I*

**Abstract Title:** Lymph node metastases in endometrial cancer: a modern assessment in the era of sentinel lymph node mapping and molecular classification

**Poster Presenter:** Aaron M. Praiss, MD

*Accepted as Poster Session I*

**Abstract Title:** Molecular and tumor microenvironmental characterization of HPV-negative invasive squamous cell carcinoma of the vulva

**Poster Presenter:** Sara Moufarrij, MD

*Accepted as Poster Session I*

**Abstract Title:** TROP2 as a novel target in uterine carcinosarcoma organoid models

**Poster Presenter:** Sara Moufarrij, MD

*Accepted as Poster Session I*

**Abstract Title:** Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers

**Poster Presenter:** Sara Moufarrij, MD

*Accepted as Poster Session I*

**Abstract Title:** Integrative analysis and machine learning application to TCGA DNA methylation, RNA-sequencing, and variant dataset in endometrial cancer for predicting recurrence

**Poster Presenter:** Jin Hwa Hong, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology clinic experience

**Poster Presenter:** Emily M. Webster, MD

*Accepted as Poster Session I*

**Abstract Title:** DDR2 depletion of cancer associated fibroblasts enhance sensitivity to PARP inhibitor in ovarian cancer

**Poster Presenter:** Alison S. McGough-Maduena, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma

**Poster Presenter:** Matt K. Wagar, MD

*Accepted as Poster Session I*

**Abstract Title:** Patterns of primary metastasis and recurrence differ among dMMR and p53abn endometrial carcinomas

**Poster Presenter:** Matt K. Wagar, MD

*Accepted as Poster Session I*

**Abstract Title:** Chemoradiotherapy response and the tumor microenvironment in a novel immunocompetent mouse model of cervical cancer

**Poster Presenter:** Tyler R. McKinnish, MD

*Accepted as Poster Session I*

**Abstract Title:** Molecular classification of clear cell endometrial carcinoma

**Poster Presenter:** Mackenzy Radolec, MD

*Accepted as Poster Session I*

**Abstract Title:** *BRCA* and homologous recombination repair deficiency testing in advanced ovarian cancer: Real world data analysis

**Poster Presenter:** Sarah E. Taylor, MD

*Accepted as Poster Session I*

**Abstract Title:** PARPi response monitoring using personalized circulating tumor DNA testing among patients with ovarian cancer

**Poster Presenter:** Michael D. Toboni, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer

**Poster Presenter:** Peter W. Ketch, MD

*Accepted as Poster Session I*

**Abstract Title:** Personalized circulating tumor DNA analysis used for ctDNA detection and response monitoring among patients with advanced or recurrent endometrial cancer

**Poster Presenter:** Michael D. Toboni, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Factors associated with human papillomavirus vaccination: Determining the effect of implicit and explicit racial bias and state laws around vaccination

**Poster Presenter:** Stephanie Alimena, MD

*Accepted as Poster Session I*

**Abstract Title:** Clinical outcomes of gynecologic tumor treatment correlate with ERK protein phosphorylation as measured by a CLIA-accredited phosphoprotein assay

**Poster Presenter:** Casey B. Williams, PharmD, MBA

*Accepted as Poster Session I*

**Abstract Title:** Hypoalbuminemia alone is not a contraindication to primary cytoreductive surgery in advanced ovarian cancer

**Poster Presenter:** Lindsey Finch

*Accepted as Poster Session I*

**Abstract Title:** Evaluation of the somatic and immunologic landscapes of primary and metastatic cervical cancer to better inform future clinical trial development

**Poster Presenter:** Mitchell Kamrava, MD, MHDS

*Accepted as Poster Session I*

**Abstract Title:** The CXCLs-CXCR2 axis modulate the cross communication between tumor-associated neutrophils and tumor cells in cervical cancer

**Poster Presenter:** Haizhou Ji, MD

*Accepted as Poster Session I*

**Abstract Title:** Ascorbate exhibits anticancer effects in pre-clinical models of serous endometrial cancer cells

**Poster Presenter:** Nikita Sinha, MD

*Accepted as Poster Session I*

**Abstract Title:** A novel ex-vivo platform for personalized treatment of metastatic ovarian cancer

**Poster Presenter:** Alain A.V. Valdivia, BS, MSc

*Accepted as Poster Session I*

**Abstract Title:** Racial disparities in survival and molecular features in Black vs. white patients with uterine serous carcinoma: An integrated study in real world registries and legacy NRG Oncology/Gynecologic Oncology Group clinical trials

**Poster Presenter:** Jordyn Tumas, MD

*Accepted as Poster Session I*

**Abstract Title:** Clinical use of machine learning-based signature for diagnosis and prognosis prediction of cisplatin resistance ovarian cancer

**Poster Presenter:** Jianfeng Zheng, M.D.

*Accepted as Poster Session I*

**Abstract Title:** Are uterine fibroids associated with delay in diagnosis of endometrial cancer?

**Poster Presenter:** Anna J. Najor, MD, MPH, MS

*Accepted as Poster Session I*

**Abstract Title:** Cost-effectiveness analysis of cancer susceptibility gene-specific prevention strategies for ovarian and breast cancer

**Poster Presenter:** Ranjit Manchanda, PhD

*Accepted as Poster Session I*

**Abstract Title:** *BRCA1* and *BRCA2* information provision online: An occasion for improvement

**Poster Presenter:** Caitlin Fierheller, PhD

*Accepted as Poster Session I*

**Abstract Title:** Female genital tract microbiome dysbiosis in endometrial cancer and atypical endometrial hyperplasia

**Poster Presenter:** Anthony Rizzo, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** MHC class II expression as a predictor of response to immune checkpoint inhibition in gynecologic malignancies

**Poster Presenter:** Erica V. Carballo, MD

*Accepted as Poster Session I*

**Abstract Title:** Unconscious bias in letters of recommendation for gynecologic oncology fellowship applicants impacts entry into the field

**Poster Presenter:** Sharonne Holtzman, MD

*Accepted as Poster Session I*

**Abstract Title:** Correlation between real-world progression-free survival and other outcomes among patients with ovarian cancer who received poly(ADP-ribose) polymerase inhibitors in the first-line maintenance setting

**Poster Presenter:** Monica Kobayashi, PhD

*Accepted as Poster Session I*

**Abstract Title:** Real-world progression-free survival in patients with homologous recombination-deficient epithelial ovarian cancer who received niraparib first-line maintenance therapy in the CHARIZMA study

**Poster Presenter:** Ritu Salani, MD, MBA

*Accepted as Poster Session I*



**Abstract Title:** Representation matters: Diversity in leadership among NCI-designated cancer centers

**Poster Presenter:** Lauren B. Davis Rivera, MD, MSEd

*Accepted as Poster Session I*

**Abstract Title:** Optimizing a patient's legacy: Lessons learned from an ovarian cancer rapid autopsy program

**Poster Presenter:** Dalia K. Omran, BS

*Accepted as Poster Session I*

**Abstract Title:** The potential impact of excluding patients with stage III epithelial ovarian cancer and no postoperative visible residual disease from the PRIMA/ENGOT-OV26/GOG-3012 Trial: The AR1ZE real-world study of niraparib first-line maintenance therapy

**Poster Presenter:** Dana M. Chase, MD

*Accepted as Poster Session I*

**Abstract Title:** Impact of Best Practice Advisory on genetic counseling referrals for young endometrial cancer patients

**Poster Presenter:** Julia Nagle, MD

*Accepted as Poster Session I*

**Abstract Title:** Endometrial cancer: Using new staging guidelines to assess old disparities

**Poster Presenter:** Ellen L. Myers, MD

*Accepted as Poster Session I*

**Abstract Title:** Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database

**Poster Presenter:** Lauren E. Dockery, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** The effect of intrawound vancomycin powder on surgical site infection in inguinal lymph node dissection: A pilot randomized control trial

**Poster Presenter:** Jessica B. DiSilvestro, MD

*Accepted as Poster Session I*

**Abstract Title:** Development of a clinically relevant orthotopic uterine carcinosarcoma mouse model using patient-derived organoids

**Poster Presenter:** Megan Gorman, MD

*Accepted as Poster Session I*

**Abstract Title:** Characterization of epithelial ovarian cancer based on multi-gene tumour testing and homologous recombination deficiency testing (COMBO)

**Poster Presenter:** Elisabeth Spenard, MD, MSc, FRCSC

*Accepted as Poster Session I*

**Abstract Title:** Geographical patterns in obesity and other lifestyle risk factors associated with endometrial cancer diagnosis and survival: The Women's Health Initiative longitudinal cohort

**Poster Presenter:** Sahana Somasegar, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** Prognostic impact of a new score using lymphocyte-to-monocyte ratios in the serum and malignant body fluid in ovarian cancer patients

**Poster Presenter:** Yeo Nyeong Yoon, MD

*Accepted as Poster Session I*

**Abstract Title:** Lymphadenectomy In clinically early epithelial ovarian cancer and survival analysis (LILAC)

**Poster Presenter:** Seung-Hyuk Shim, MD

*Accepted as Poster Session I*

**Abstract Title:** BRCA awareness and testing experience in the U.K. Jewish population: A qualitative study

**Poster Presenter:** Caitlin Fierheller, PhD

*Accepted as Poster Session I*

**Abstract Title:** Diagnostic and prognostic accuracy of exosomal miRNA-based signature for endometrial cancer

**Poster Presenter:** Jianfeng Zheng, MD

*Accepted as Poster Session I*

**Abstract Title:** Duration of bleeding prior to endometrial cancer diagnosis: An opportunity to rethink our approach to detection and diagnosis in at risk groups

**Poster Presenter:** Amelia M. Jernigan, MD

*Accepted as Poster Session I*

**Abstract Title:** Is presumed clinical stage one endometrial cancer in PET-CT and MRI, truly stage one in surgical staging?

**Poster Presenter:** Sang Wun Kim

*Accepted as Poster Session I*

**Abstract Title:** Targeting mediator kinases CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma

**Poster Presenter:** Wade C. Barton, MD, PharmD

*Accepted as Poster Session I*

**Abstract Title:** A programmed cell death-related signature in predicting cisplatin reactivity in ovarian cancer

**Poster Presenter:** Xintong Cai, MD

*Accepted as Poster Session I*

**Abstract Title:** A multi-modal intervention to revitalize a gynecologic oncology tissue bank increases patient enrollment and expands standardized sample collection

**Poster Presenter:** Amanda Compadre, MD

*Accepted as Poster Session I*

**Abstract Title:** Knockout of cancer biomarker HE4 in the gynecologic tract leads to fibrosis and early infertility.

**Poster Presenter:** Cameron W.A. Snyder, AS

*Accepted as Poster Session I*

**Abstract Title:** 3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer

**Poster Presenter:** Helen Mackay, MD

*Accepted as Poster Session I*

**Abstract Title:** Exploring U.S. Hispanic origin groups diagnosed with uterine cancer: Are there disparities?

**Poster Presenter:** Caitlin R. Johnson, MPH

*Accepted as Poster Session I*

**Abstract Title:** Check the test: Does endometrial thickness perform well in a diverse cohort with postmenopausal bleeding?

**Poster Presenter:** Angela Nolin, MD

*Accepted as Poster Session I*

**Abstract Title:** Impact of the tumor microenvironment in splenic metastasis in high-grade serous ovarian cancer revealed by quantitative proteomics

**Poster Presenter:** Suzanne C. Jokajty, MD

*Accepted as Poster Session I*

**Abstract Title:** Racial disparities and religious preferences: Prospective study of palliative care preferences among patients with gynecologic cancer

**Poster Presenter:** Catherine E. Hermann, MD

*Accepted as Poster Session I*

**Abstract Title:** Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care

**Poster Presenter:** Wade C. Barton, MD, PharmD

*Accepted as Poster Session I*

**Abstract Title:** Language as a barrier to clinical trial enrollment: Identifying methods to improve clinical trial enrollment in minority and non-English speaking patients

**Poster Presenter:** Wade C. Barton, MD, PharmD

*Accepted as Poster Session I*

**Abstract Title:** Epidural analgesia as part of an enhanced recovery after surgery pathway in gynecologic surgery

**Poster Presenter:** Charles W. Ashley

*Accepted as Poster Session I*

**Abstract Title:** Deep quantitative proteomics identifies elevated MUC16 in low compared to high-grade serous ovarian carcinoma

**Poster Presenter:** Christopher Tarney

*Accepted as Poster Session I*

**Abstract Title:** Primary survival outcomes between metastatic sites in ovarian cancer

**Poster Presenter:** Natalie Moshayedi, BA

*Accepted as Poster Session I*

**Abstract Title:** Targeting ovarian cancer cell attachment to the peritoneum

**Poster Presenter:** Martins Ayoola, MD

*Accepted as Poster Session I*

**Abstract Title:** Prognostic value of aggressive histology in surgically staged clinically uterine-confined endometrial carcinoma

**Poster Presenter:** Christian Dagher, MD

*Accepted as Poster Session I*

**Abstract Title:** Worth the pain? Postoperative epidural anesthesia use in gynecologic surgery

**Poster Presenter:** Nayla Labban, MD

*Accepted as Poster Session I*

**Abstract Title:** Geospatial analysis of miRNA in ovarian cancer

**Poster Presenter:** Victoria Wang, MD

*Accepted as Poster Session I*

**Abstract Title:** Diagnostic yield and characteristics of germline-positive genetic testing ordered by obstetricians and gynecologists in female patients with a personal history of cancer

**Poster Presenter:** Sarah S. Lee, MD

*Accepted as Poster Session I*

**Abstract Title:** Systematic review and meta-analysis: The incidence rate of breast cancer in ovarian cancer patients with *BRCA* mutation

**Poster Presenter:** 원덕 주, MD

*Accepted as Poster Session I*

**Abstract Title:** Identification of high-grade endometrioid-like serous carcinoma of the ovary through multi-omics analysis: JGOG3025-TR2 study

**Poster Presenter:** Shiro Takamatsu, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Comprehensive genomic profiling of circulating tumor DNA is highly concordant with solid tumor DNA and identifies additional actionable mutations in advanced ovary and endometrial cancer patients

**Poster Presenter:** John Nakayama, MD

*Accepted as Poster Session I*

**Abstract Title:** Combinatorial PARP and HDAC inhibition synergistically promotes cell death and overcomes cisplatin treatment tolerance in cervical cancer cell lines

**Poster Presenter:** Steven B. Holloway, MD

*Accepted as Poster Session I*

**Abstract Title:** Clarifying intratumoral heterogeneity in ovarian cancer via transcriptomic analysis of the PI3K/AKT/mTOR pathway

**Poster Presenter:** Yang Shen, MD

*Accepted as Poster Session I*

**Abstract Title:** CXCL13 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors

**Poster Presenter:** Yang Shen, MD

*Accepted as Poster Session I*

**Abstract Title:** Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis

**Poster Presenter:** Yang Shen, MD

*Accepted as Poster Session I*

**Abstract Title:** lncN74/miR762/NgBR acts as key ceRNA network regulates the Ras/Akt signaling pathway to promote the development of endometrial cancer

**Poster Presenter:** Wenwen Zhang, PhD

*Accepted as Poster Session I*

**Abstract Title:** Clinical significance of CD101+PD-1+CD8 T cells in malignant ascites in patients with advanced ovarian cancer

**Poster Presenter:** Dahye LEE, MD

*Accepted as Poster Session I*

**Abstract Title:** Peritonectomy and resection of mesentery during visceral-peritoneal debulking in patients with stage IIIC-IV ovarian cancer: A phase I-II trial

**Poster Presenter:** Matteo Marchetti, MD

*Accepted as Poster Session I*

**Abstract Title:** Feasibility of laparoscopic visceral-peritoneal debulking in patients with stage III-IV ovarian cancer: The ULTRA-LAP trial pilot study

**Poster Presenter:** Roberto Tozzi, MD

*Accepted as Poster Session I*

**Abstract Title:** The role of NKG2D-MICA in the immune escape mechanism of epithelial ovarian cancer

**Poster Presenter:** Yuanchun Fan, MA

*Accepted as Poster Session I*

**Abstract Title:** Glycometabolism and lipid metabolism related genes predict the prognosis of endometrial carcinoma and their effects on tumor cells

**Poster Presenter:** Xuefen Lin

*Accepted as Poster Session I*



**Abstract Title:** Hyperthermic intraperitoneal chemotherapy for stage IV epithelial ovarian cancer: A critical appraisal of indications and clinical implications

**Poster Presenter:** Joo-Hyuk Son, MD

*Accepted as Poster Session I*

**Abstract Title:** Frequency and outcomes of co-mutations according to ProMisE classifiers in endometrial cancer

**Poster Presenter:** Rouba Ali-Fehmi, MD

*Accepted as Poster Session I*

**Abstract Title:** A study of cadonilimab combined with standard therapy for the first-line treatment of recurrent or metastatic cervical cancer

**Poster Presenter:** Jiahui Yang, MA

*Accepted as Poster Session I*

**Abstract Title:** Molecular classification of endometrial cancer in a Brazilian cohort

**Poster Presenter:** Ana Carla Franco Ubinha

*Accepted as Poster Session I*

**Abstract Title:** Is it possible to predict the postoperative stage in early-stage endometrial cancer patients based on TCGA classification of preoperative dilatation & curettage tissue? Efforts for personalized surgical approaches

**Poster Presenter:** 지현 이, MD

*Accepted as Poster Session I*

**Abstract Title:** Mechanistic study of EPHB2 affecting the sensitivity of cervical cancer radiotherapy by regulating autophagy through AKT/mTor pathway

**Poster Presenter:** Li Liu

*Accepted as Poster Session I*

**Abstract Title:** Cracking the code: Understanding molecular signatures in ovarian cancer subgroups undergoing primary treatment

**Poster Presenter:** Amma Asare, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Current trends in high-risk human papillomavirus types and association with age and race/ethnicity in an inner-city population

**Poster Presenter:** Kimberly Levinson, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Safety and feasibility of same day discharge in robotic hysterectomy and staging for endometrial cancer: A multicenter review

**Poster Presenter:** Leah O. Grcevich, DO

*Accepted as Poster Session I*

**Abstract Title:** Spatial profiling of mismatch repair deficient endometrial tumors identifies patterns associated with recurrence and response to immune checkpoint therapy

**Poster Presenter:** Catherine E. Hermann, MD

*Accepted as Poster Session I*

**Abstract Title:** Validation of NGS-based comprehensive genomic profiling for the molecular classification of endometrial carcinomas into prognostic subgroups

**Poster Presenter:** Brian M. Slomovitz, MD

*Accepted as Poster Session I*

**Abstract Title:** Attenuated titin protein expression correlates with poor prognosis in ovarian cancer

**Poster Presenter:** Ghassan M. Saed, PhD

*Accepted as Poster Session I*

**Abstract Title:** Does cancer appearance reflect genetic status? The relationship between the gross appearance of high-grade serous ovarian cancer and *BRCA* mutation status

**Poster Presenter:** Deanna Glassman, MD

*Accepted as Poster Session I*

**Abstract Title:** Treatment monitoring utilizing ctDNA-based molecular residual disease detection in patients with recurrent endometrial cancer and recurrent platinum-resistant ovarian cancer

**Poster Presenter:** Floor J. Backes, MD

*Accepted as Poster Session I*

**Abstract Title:** Use of a DNA methyltransferase inhibitor and poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) in the treatment of PARPi-resistant high-grade serous ovarian cancer

**Poster Presenter:** Anousheh Shafa, MD

*Accepted as Poster Session I*

**Abstract Title:** Serous tubal intraepithelial carcinoma in high-risk patients: Age, risk of primary peritoneal cancer, and precursor escape in a comprehensive single institution study of 35 cases

**Poster Presenter:** Eliane Aoun, MD

*Accepted as Poster Session I*

**Abstract Title:** Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?

**Poster Presenter:** Maureen E. Byrne, MD, MSCR

*Accepted as Poster Session I*

**Abstract Title:** Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer

**Poster Presenter:** Grace Duininck, MD

*Accepted as Poster Session I*

**Abstract Title:** Chromobox2/Y-box binding protein 1 axis drives chemoresistance in high-grade serous carcinoma: Exploring novel therapeutic strategies

**Poster Presenter:** Lindsay W. Brubaker, MD

*Accepted as Poster Session I*

**Abstract Title:** Real-world *BRCA1/2* and homologous recombination deficiency testing dynamics and time to treatment discontinuation on PARP inhibitor first-line maintenance in patients with epithelial ovarian cancer

**Poster Presenter:** Rebecca A. Previs, MD, MS

*Accepted as Poster Session I*

**Abstract Title:** p53 functional status is associated with survival in high-grade serous ovarian cancer patients with copy number signature 1

**Poster Presenter:** Theresa M. Kuhn, MD

*Accepted as Poster Session I*

**Abstract Title:** Prevalence of targetable and potentially targetable alterations in metastatic/recurrent cervical cancer specimens in a large genomic dataset

**Poster Presenter:** John J. Wallbillich, MD

*Accepted as Poster Session I*

**Abstract Title:** Inhibiting mitochondria potentiates PARPi triggered STING dependent immune response in preclinical models of epithelial ovarian cancer

**Poster Presenter:** Miriana Hijaz, MD

*Accepted as Poster Session I*

**Abstract Title:** The cervical and tumor-associated microbiome in Botswanan women with HIV diagnosed with high-grade cervical dysplasia and squamous cell carcinoma of the cervix

**Poster Presenter:** Travis T. Sims, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Determining the immunologic basis of pregnancy-induced oncoprotection in *BRCA1* hereditary breast cancer

**Poster Presenter:** Dhivyaa Anandan, BA

*Accepted as Poster Session I*

**Abstract Title:** Systematic review: Early ovarian cancer detection in the age of fallopian tube precursors

**Poster Presenter:** Ashley L. Greenwood, MD

*Accepted as Poster Session I*

**Abstract Title:** Decoding health disparities: An analysis of endometrial *TP53* mutations, race, and social determinants of health

**Poster Presenter:** Eric Rios-Doria, MD

*Accepted as Poster Session I*

**Abstract Title:** Healthcare utilization by endometrial cancer survivors

**Poster Presenter:** Nerlyne Desravines, MD

*Accepted as Poster Session I*

**Abstract Title:** HMGA2 induce radioresistance through DNA damage repair and autophagy pathways in cervical cancer

**Poster Presenter:** Yanhong Li

*Accepted as Poster Session I*

**Abstract Title:** Association of HPV-independent gastric adenocarcinoma with a higher risk of mortality in locally-advanced cases

**Poster Presenter:** Stephanie Cham, MD

*Accepted as Poster Session I*

**Abstract Title:** The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study

**Poster Presenter:** Ido Laskov, MD

*Accepted as Poster Session I*

**Abstract Title:** Development of a deep learning-based auto-segmentation algorithm for peritoneal metastases using computed tomography image analysis of ovarian cancer

**Poster Presenter:** Noh Hyun Park, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Salvage surgery for patients with residual disease after concurrent chemoradiation therapy for locally-advanced cervical cancer: A prospective, single-arm clinical study

**Poster Presenter:** Dongling Zou, PHD

*Accepted as Poster Session I*

**Abstract Title:** Fibroblast growth factor 7 is a promising target in the process of ovarian cancer tumor attachment to prevent metastasis

**Poster Presenter:** Brooke Meelheim, DO

*Accepted as Poster Session I*

**Abstract Title:** LDH-C4 is a potential autophagy-related prognosis biomarker with functional significance in cervical cancer

**Poster Presenter:** Shan Jiang

*Accepted as Poster Session I*

**Abstract Title:** Outcomes of niraparib first line maintenance in patients with *BRCA* wildtype advanced ovarian cancer in a real world clinical setting

**Poster Presenter:** Rachel Kupets, MD

*Accepted as Poster Session I*

**Abstract Title:** PLK1 inhibitor onvansertib demonstrates anti-tumorigenic effects in serous uterine cancer cell lines

**Poster Presenter:** Jennifer G. Haag, MD

*Accepted as Poster Session I*

**Abstract Title:** Individualised cell-free DNA biomarker analysis for management of women with E.C.

**Poster Presenter:** Jure Knez, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** Notch inhibition with gamma secretase inhibitor increases apoptosis of uterine leiomyosarcoma cells

**Poster Presenter:** Alexander J. Fife, MD

*Accepted as Poster Session I*

**Abstract Title:** Vitamin D significantly inhibits carcinogenesis in the Mogp-TAg mouse model of fallopian tube cancer

**Poster Presenter:** Omar L. Nelson, PhD

*Accepted as Poster Session I*

**Abstract Title:** Opportunity for increasing applicant diversity in gynecologic oncology fellowship programs

**Poster Presenter:** Priyanka Raju, MD

*Accepted as Poster Session I*

**Abstract Title:** BET inhibition modulates the functional phenotype and plasticity of tumor associated macrophages and improve survival: Next frontier in overcoming immunotherapy resistance in ovarian cancer

**Poster Presenter:** Shaheen Mahira, PhD

*Accepted as Poster Session I*

**Abstract Title:** COPS5 inhibition targets nucleotide excision repair and homologous recombination to enhance platinum chemotherapy response in ovarian cancer

**Poster Presenter:** Mary M. Mullen, MD

*Accepted as Poster Session I*

**Abstract Title:** Mismatch repair-deficiency and tumor mutational burden are associated with higher microbiome diversity in the reproductive tract

**Poster Presenter:** Maria M. Rubinstein, MD

*Accepted as Poster Session I*

**Abstract Title:** Targeting BRD4 with BET inhibition synergizes with anti-HER2 therapy and overcome resistance in HER2 amplified uterine serous cancer

**Poster Presenter:** Mohamad H. Jawadi, MD

*Accepted as Poster Session I*

**Abstract Title:** Sentinel lymph node size alone should not preclude sentinel lymph node biopsy for endometrial cancer patients undergoing surgical staging

**Poster Presenter:** Paulina J. Haight, MD

*Accepted as Poster Session I*

**Abstract Title:** Cervicovaginal metabolome is predictive of endometrial cancer and tumor characteristics and leveraged for risk stratification

**Poster Presenter:** Dana M. Chase, MD

*Accepted as Poster Session I*

**Abstract Title:** Characterization of the female reproductive tract microbiome in epithelial ovarian cancer patients

**Poster Presenter:** Natalie M. Clark, MD

*Accepted as Poster Session I*



**Abstract Title:** ROR2/Wnt5a signaling regulates early tumor cell invasion and metastasis in ovarian cancer

**Poster Presenter:** Whitney R. Grither, MD, PhD

*Accepted as Poster Session I*

**Abstract Title:** External validation of a diagnostic nomogram based on clinical parameters and nutritional index for predicting vaginal invasion in stage IB-IIA cervical cancer

**Poster Presenter:** Ning Xie, MA

*Accepted as Poster Session I*

**Abstract Title:** The pattern of homologous recombination associated gene mutations in circulating tumor DNA and solid tumors from pretreatment ovarian cancer patients reveals potentially useful patterns of mutation

**Poster Presenter:** John Nakayama, MD

*Accepted as Poster Session I*

**Abstract Title:** RE1 transcription factor is decreased in endometrial cancer

**Poster Presenter:** Yasmin Abedin, MD

*Accepted as Poster Session I*

**Abstract Title:** Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells

**Poster Presenter:** Anh Q. Nguyen, MD

*Accepted as Poster Session I*

**Abstract Title:** Machine learning for prediction of concurrent endometrial carcinoma patients diagnosed with an endometrial intraepithelial neoplasia.

**Poster Presenter:** Gabriel Levin, MD

*Accepted as Poster Session I*

**Abstract Title:** The significance of gynecologic oncology presence in a community based obstetric and gynecology residency program

**Poster Presenter:** Maya M. Hicks, MD

*Accepted as Poster Session I*

**Abstract Title:** Impact of geographic region of birth on overall survival in Hispanic women with endometrial cancer

**Poster Presenter:** Alyssa J. Mercadel, MD

*Accepted as Poster Session I*

**Abstract Title:** The impact of TCGA status in patients with recurrent endometrioid endometrial carcinoma treated with secondary cytoreductive surgery

**Poster Presenter:** Mary Kathryn Abel, MD, MAS

*Accepted as Poster Session I*

**Abstract Title:** Weakly supervised deep learning-based prognostic model for AI-assisted prospective clinical investigation of cervical cancer

**Poster Presenter:** Chen-ying Ma, MD

*Accepted as Poster Session I*

**Abstract Title:** Changes in immune checkpoint receptors on tumor-infiltrating CD8 T cells after chemoradiation therapy associated with the prognosis of locally-advanced cervical cancer

**Poster Presenter:** Kyunghim Lee, MD

*Accepted as Poster Session I*

**Abstract Title:** Uptake of ovarian cancer genetic testing by disaggregated racial and ethnic subgroups

**Poster Presenter:** Sarah S. Lee, MD

*Accepted as Poster Session I*

**Abstract Title:** Poor chemotherapy responses post PARPi treatment in ovarian cancer. Need for novel therapeutics?

**Poster Presenter:** Michalis Liontos, PhD

*Accepted as Poster Session I*

**Abstract Title:** Tetanus toxoid expression slows progression and improves response to immunotherapy in ovarian cancer pre-clinical models

**Poster Presenter:** Lauren R. Scanlon, MD

*Accepted as Poster Session I*

**Abstract Title:** Access to cervical cancer clinical trials for patients living with HIV: An area for improvement

**Poster Presenter:** Lauren E. Gottshall, MD

*Accepted as Poster Session I*

**Abstract Title:** The landscape of targetable gene mutations in neuroendocrine cervical cancer

**Poster Presenter:** Muhammad Danyal Ahsan, MD

*Accepted as Poster Session I*

**Abstract Title:** HPV-negative cervical cancer: Exploring targetable mutations using next-generation sequencing

**Poster Presenter:** Muhammad Danyal Ahsan, MD

*Accepted as Poster Session I*

**Abstract Title:** The escalating incidence of advanced stage cervical cancer in underrepresented patients in the U.S.

**Poster Presenter:** Teresa Palkowski, MD

*Accepted as Poster Session I*

**Abstract Title:** Characteristics and outcomes of geriatric patients with advanced solid tumors enrolled in a single-center, phase I clinical trial program

**Poster Presenter:** Hadi Erfani, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** Race, ethnicity and gender in academic gynecology oncology leadership

**Poster Presenter:** Jessica Velasquez, MD

*Accepted as Poster Session I*

**Abstract Title:** Concurrent laparoscopic hysterectomy and bariatric surgery for early-stage endometrial cancer and endometrial intraepithelial neoplasia: Lessons learned from an interdisciplinary prospective feasibility trial

**Poster Presenter:** Alexandra Bercow, MD

*Accepted as Poster Session I*

**Abstract Title:** Proteogenomics identifies immunogenic HLA-I cryptic peptides in ovarian cancer

**Poster Presenter:** Marion Curtis, PhD

*Accepted as Poster Session I*

**Abstract Title:** Frequency and clinicopathologic profile of genetic co-mutations in women with gynecologic and breast cancer in a multiethnic urban cancer center

**Poster Presenter:** Nicole Lugo Santiago, MD

*Accepted as Poster Session I*

**Abstract Title:** A RADD analysis of DNA damage in endometrial cancer specimens

**Poster Presenter:** Kevin Lee, PhD

*Accepted as Poster Session I*

**Abstract Title:** Safety of apixaban when compared to enoxaparin for postoperative venous thromboembolism prophylaxis among gynecologic cancer patients

**Poster Presenter:** Melissa Foy, DO

*Accepted as Poster Session I*

**Abstract Title:** Training the surgeon's eye: Correlation of surgeon radiology assessment to laparoscopic disease site scoring in advanced ovarian cancer over a 10-year QI program

**Poster Presenter:** Roni Nitecki, MD, MPH

*Accepted as Poster Session I*

**Abstract Title:** HER2 expression by next-generation sequencing versus immunohistochemistry in uterine serous carcinoma at a major gynecologic oncology referral center in the Southeast

**Poster Presenter:** Alexandra Blackman, MD

*Accepted as Poster Session I*

**Abstract Title:** Discrepancies between clinical trial availability and the incidence of gynecologic cancers

**Poster Presenter:** Andrea Nanez, MD

*Accepted as Poster Session I*

**Abstract Title:** The role of chronic stress, tumor immunity and DNA damage in cervix cancer

**Poster Presenter:** Tanvi V. Joshi, MD

*Accepted as Poster Session I*

**Abstract Title:** Effect of steroids on cisplatin-mediated cytotoxicity

**Poster Presenter:** Tanvi V. Joshi, MD

*Accepted as Poster Session I*

**Abstract Title:** Generation of an organoid model of a STIC lesion from a MADM mouse model for pre-malignant ovarian cancer

**Poster Presenter:** Sagar K. Chokshi, DO, MS

*Accepted as Poster Session I*

**Abstract Title:** HER-2 Status, MMR and P53 expression among endometrial cancer patients

**Poster Presenter:** Kathryn Allen, BS

*Accepted as Poster Session I*

**Abstract Title:** The role of ASIC2 and calcium influx in epithelial ovarian cancer pathogenesis

**Poster Presenter:** Kevin Lee, PhD

*Accepted as Poster Session I*

**Abstract Title:** Allostatic load and its impact on outcomes in cervical cancer

**Poster Presenter:** Tanvi V. Joshi, MD

*Accepted as Poster Session I*

**Abstract Title:** Exploring the DNA damage and repair landscape in the spontaneous hen model of ovarian cancer

**Poster Presenter:** Jennifer M. Scalici, MD

*Accepted as Poster Session I*

**Abstract Title:** Barriers and facilitators to cervical cancer screening among American Indian/Alaska Native individuals aged 50-64 years

**Poster Presenter:** Jessica B. DiSilvestro, MD

*Accepted as Poster Session II*

**Abstract Title:** Trends in benign hysterectomies performed by gynecologic oncologists, 2015-2021: A National Surgical Quality Improvement Program analysis

**Poster Presenter:** Annalyn Welp, MD

*Accepted as Poster Session II*

**Abstract Title:** Assessing attitudes towards and uptake of human papillomavirus vaccination among U.S. medical residents in high-exposure risk specialties

**Poster Presenter:** Madison Oxford, BA

*Accepted as Poster Session II*

**Abstract Title:** Canadian management of serous tubal intraepithelial carcinoma (Can-STIC)

**Poster Presenter:** Elisabeth Spenard, MD, MSc, FRCSC

*Accepted as Poster Session II*

**Abstract Title:** Human papillomavirus and time to cervical cancer development among active duty service women

**Poster Presenter:** Megan K. Allen, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Evaluation of a quality improvement initiative to screen for and treat nutritional causes of anemia among patients with gynecologic malignancies on systemic treatment

**Poster Presenter:** Olivia W. Foley, MD

*Accepted as Poster Session II*

**Abstract Title:** A comprehensive evaluation of toxicity after radical hysterectomy or trachelectomy and postoperative pelvic intensity-modulated radiation therapy for cervical cancer

**Poster Presenter:** Madison E. Miller, MD

*Accepted as Poster Session II*

**Abstract Title:** Ridesharing as transportation assistance in gynecologic oncology: A pilot study

**Poster Presenter:** Anna Jo B. Smith, MD

*Accepted as Poster Session II*

**Abstract Title:** Can CA-125/CEA ratio be used for the differential diagnosis between ovarian and non-ovarian cancers? A cross-sectional study

**Poster Presenter:** Jeferson Zanon, MD, MSc

*Accepted as Poster Session II*

**Abstract Title:** Questionnaire survey on cervical cancer screening and HPV awareness among patients at a local cancer center in Japan

**Poster Presenter:** Kazuto Nakamura, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Trends and disparities in the provision of salpingectomy for surgical sterilization: The underbelly of coding, billing and reimbursement

**Poster Presenter:** Dana Hazimeh, MD

*Accepted as Poster Session II*

**Abstract Title:** Maintenance bevacizumab following chemotherapy improves survival in patients with advanced and recurrent cervical cancer

**Poster Presenter:** Michelle L. Kuznicki, MD

*Accepted as Poster Session II*

**Abstract Title:** Demographics in early versus late-stage endometrial cancer: A National Cancer Database review

**Poster Presenter:** Kristine Au, BS

*Accepted as Poster Session II*



**Abstract Title:** Oncologists' perspectives on discussing 'cure' with patients with ovarian cancer

**Poster Presenter:** Robert Coleman, MD

*Accepted as Poster Session II*

**Abstract Title:** Dosimetry, toxicity, and outcomes of medically inoperable endometrial cancer patients treated with Y-tandem brachytherapy

**Poster Presenter:** Caitlin Reichard, MA

*Accepted as Poster Session II*

**Abstract Title:** A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer

**Poster Presenter:** Jie Lin, MD

*Accepted as Poster Session II*

**Abstract Title:** COPANIRA: Phase Ib trial of copanlisib and niraparib in recurrent ovarian and endometrial cancer

**Poster Presenter:** Allison L. Brodsky, MD

*Accepted as Poster Session II*

**Abstract Title:** Cervical cancer screening: Solutions for those who have experienced trauma

**Poster Presenter:** Jessica Currier, PhD

*Accepted as Poster Session II*

**Abstract Title:** Machine learning for ovarian cancer screening: A novel approach to an age-old dilemma

**Poster Presenter:** Graham C. Chapman, MD

*Accepted as Poster Session II*

**Abstract Title:** Lymph node evaluation for endometrial intraepithelial neoplasia: An analytic model

**Poster Presenter:** Allison R. Walker, MD

*Accepted as Poster Session II*

**Abstract Title:** Assessing end-of-life care access in patients with terminal gynecologic cancer at a major urban institution

**Poster Presenter:** Riva Letchinger

*Accepted as Poster Session II*

**Abstract Title:** The effect of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy

**Poster Presenter:** Quinn M. Kistenfeger, MD

*Accepted as Poster Session II*

**Abstract Title:** Gynecologic oncology patients with severe mental illness diagnosis are more likely to experience adverse outcomes during hospitalizations for cancer-directed treatment

**Poster Presenter:** Ann M. Cathcart, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Cross-sectional survey of preparedness for gynecologic oncology fellowship among recent gynecologic oncology graduates

**Poster Presenter:** Katelyn Tondo-Steele, DO

*Accepted as Poster Session II*

**Abstract Title:** Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center

**Poster Presenter:** Victoria Diamond, BS, MD

*Accepted as Poster Session II*

**Abstract Title:** Do it!': Gynecologic cancer clinical trial participants' advice to others and perspectives

**Poster Presenter:** Annie E. Ellis

*Accepted as Poster Session II*

**Abstract Title:** Rare tumors in gynecologic oncology fellowship: A novel longitudinal integrated curriculum initiative

**Poster Presenter:** Lindsay W. Brubaker, MD

*Accepted as Poster Session II*

**Abstract Title:** Clearance of high-risk HPV after LLETZ of early-stage invasive cervical cancer or adenocarcinoma in situ has a high correlation with absence of residual cancer

**Poster Presenter:** Meirav Schmidt, MD

*Accepted as Poster Session II*

**Abstract Title:** Fertility-sparing surgery versus standard surgery for early-stage cervical cancer: Five-year life expectancies by tumor size

**Poster Presenter:** Nuria Agusti, MD

*Accepted as Poster Session II*

**Abstract Title:** Anlotinib plus penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06)

**Poster Presenter:** Qin Xu

*Accepted as Poster Session II*

**Abstract Title:** Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and cervical cancers

**Poster Presenter:** Mustafa Syed, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer: Japanese Gynecologic Oncology Group study

**Poster Presenter:** Hiroko Machida, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Cause of death following conservative, non-surgical treatment for seasoned patients with early-stage, low-grade endometrial cancer

**Poster Presenter:** Zachary S. Anderson, MD

*Accepted as Poster Session II*

**Abstract Title:** Conservative, non-surgical treatment for young patients with early-stage, low-grade endometrial cancer: Population-level trends and oncologic outcomes

**Poster Presenter:** Aaron D. Masjedi, MD

*Accepted as Poster Session II*

**Abstract Title:** GOG-3084: A phase II trial of ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers

**Poster Presenter:** Christine Ingleby, DPhil

*Accepted as Poster Session II*

**Abstract Title:** As easy as EMR? Utilization of the electronic medical record to encourage thromboprophylaxis for gynecologic oncology patients with a high Khorana score

**Poster Presenter:** Taryn Boucher, MD

*Accepted as Poster Session II*

**Abstract Title:** Survival after sentinel lymph node biopsy for early cervical cancers: A systematic review and meta-analysis

**Poster Presenter:** Giulia Parpinel, MD

*Accepted as Poster Session II*

**Abstract Title:** Oncologic outcomes among patients undergoing fertility-sparing treatment of atypical hyperplasia and grade one cancer of the endometrium using progestin therapy: Results of a novel, specialized oncofertility program

**Poster Presenter:** Oleksandra Dzyubak, MD

*Accepted as Poster Session II*

**Abstract Title:** XMT-1660: A phase I, first-in-human trial of a B7-H4-directed dolasynthen antibody drug conjugate in ovarian, endometrial, and breast cancers

**Poster Presenter:** Robert A. Burger, MD

*Accepted as Poster Session II*

**Abstract Title:** Real-world time-to-event outcomes in patients with ovarian cancer receiving olaparib maintenance therapy in the United States

**Poster Presenter:** Elizabeth A. Szamreta, PhD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Evaluating nutrition in advanced ovarian cancer: Which biomarker works best?

**Poster Presenter:** Diletta Fumagalli, MD

*Accepted as Poster Session II*

**Abstract Title:** The evolving landscape of molecular profiling in early-stage endometrial cancer: An NRG Oncology cooperative group mixed-methods study

**Poster Presenter:** Elise M. Wilson, MD

*Accepted as Poster Session II*

**Abstract Title:** Impact of FIGO 2023 staging criteria for endometrial cancer on stage migration and survival outcomes

**Poster Presenter:** Justin W.J. Lim, MD

*Accepted as Poster Session II*

**Abstract Title:** Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multi-center study in China

**Poster Presenter:** Yang Shen, MD

*Accepted as Poster Session II*

**Abstract Title:** The impact of Medicaid expansion on cervical cancer outcomes

**Poster Presenter:** Michael Danziger, MD, ScM

*Accepted as Poster Session II*

**Abstract Title:** Improved outcomes with neoadjuvant chemotherapy in women with advanced stage endometrial cancer including disparity reduction in Black women

**Poster Presenter:** Grace M. Lee, MD

*Accepted as Poster Session II*

**Abstract Title:** A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301

**Poster Presenter:** Rachel N. Grisham, MD

*Accepted as Poster Session II*

**Abstract Title:** Assessing the impact of brachytherapy boost in intermediate-risk, early-stage cervical cancer treatment

**Poster Presenter:** Nuria Agusti, MD

*Accepted as Poster Session II*

**Abstract Title:** Evaluating ChatGPT's performance in answering common patient questions on cervical cancer

**Poster Presenter:** Anthony Do, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Physician variation in adopting prophylactic salpingectomy at the time of postpartum sterilization for ovarian cancer risk reduction

**Poster Presenter:** Xiao Xu, PhD

*Accepted as Poster Session II*

**Abstract Title:** The efficacy and safety of combining anlotinib with albumin-bound paclitaxel and cisplatin in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase II trial

**Poster Presenter:** Fufeng Gao, MA

*Accepted as Poster Session II*

**Abstract Title:** Molecular subtypes of endometrioid endometrial cancer predict rates of lymph node and ovarian metastasis at the time of surgical staging

**Poster Presenter:** Isabela Covelli Velez, MD

*Accepted as Poster Session II*

**Abstract Title:** Voices of women with low-grade serous ovarian cancer: Results from a multinational survey

**Poster Presenter:** Charlotte C. Sun, DrPH, MPH

*Accepted as Poster Session II*

**Abstract Title:** A prospective study on the application of para-aortic lymph node metastasis prediction model in locally-advanced cervical cancer and its effect on prognosis (CQGOG0109)

**Poster Presenter:** Dongling Zou, PhD

*Accepted as Poster Session II*

**Abstract Title:** CDK4/6 inhibitor dalpiciclib combined with nonsteroidal aromatase inhibitors in estrogen receptor-positive recurrent/metastatic ovarian cancer and uterine neoplasms

**Poster Presenter:** Huijuan Yang

*Accepted as Poster Session II*

**Abstract Title:** A phase II, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer: Final efficacy analysis and correlative studies

**Poster Presenter:** Elizabeth K. Lee, MD

*Accepted as Poster Session II*

**Abstract Title:** Electronic patient reported outcomes improve postoperative gynecology oncologic care in a rural academic center

**Poster Presenter:** Linh H. Nguyen, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** The role of gynecologic oncology provider involvement in intraoperative consults by benign OBGYNs

**Poster Presenter:** Allison E. Grubbs, MD

*Accepted as Poster Session II*

**Abstract Title:** Implementation of immunotherapy in recurrent endometrial cancer: A real-world study

**Poster Presenter:** Anna Jo B. Smith, MD

*Accepted as Poster Session II*

**Abstract Title:** Lymph node dissection after neoadjuvant chemotherapy improves overall survival in clinical stage III endometrial cancer

**Poster Presenter:** Megan E. Lander, MD

*Accepted as Poster Session II*

**Abstract Title:** Validation of the safety and efficacy of apixaban for postoperative thromboembolism prophylaxis among patients with gynecologic malignancies



**Poster Presenter:** Jessica L. Floyd, MD

*Accepted as Poster Session II*

**Abstract Title:** Impact of age on hematologic toxicities in patients with node negative cervical cancer treated with chemoradiotherapy: A prospective observational study

**Poster Presenter:** John Mohan Mathew, MD

*Accepted as Poster Session II*

**Abstract Title:** A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer or *MUC16+* endometrial cancer: Trial in progress update

**Poster Presenter:** Joe Bolton, MSc

*Accepted as Poster Session II*

**Abstract Title:** Hospital frailty risk score predicts postoperative morbidity in women undergoing ovarian cancer debulking: A National Inpatient Sample analysis

**Poster Presenter:** David Samuel, MD

*Accepted as Poster Session II*

**Abstract Title:** Tumor risk factors are not consistently used to make postoperative radiation recommendations: A multivariate analysis

**Poster Presenter:** Christine G. Nguyen Dawson, MD

*Accepted as Poster Session II*

**Abstract Title:** Pumping in the OR: A mixed methods study of family building and parenting among current and past gynecologic oncology fellows

**Poster Presenter:** Mary N. Towner, MD

*Accepted as Poster Session II*

**Abstract Title:** Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center

**Poster Presenter:** Halle H. Thannickal, BS

*Accepted as Poster Session II*

**Abstract Title:** Internal fellowship candidate match rates in obstetrics and gynecology before and after the wide-spread adoption of virtual interviews post-COVID

**Poster Presenter:** Hannah McLaughlin, MD

*Accepted as Poster Session II*

**Abstract Title:** Hormone replacement therapy in ovarian cancer survivors: Clinical considerations to optimize patient care

**Poster Presenter:** Nora Badiner, MD

*Accepted as Poster Session II*

**Abstract Title:** Treatment patterns and outcomes of patients with stage I, high-risk endometrial cancer histologies

**Poster Presenter:** Naaman Mehta, MD

*Accepted as Poster Session II*

**Abstract Title:** Conversion from minimally invasive surgery to open surgery among endometrial cancer patients in the SGO clinical outcomes registry

**Poster Presenter:** Abdelrahman Yousif, MD

*Accepted as Poster Session II*

**Abstract Title:** Experience of healthcare discrimination among individuals with a history of gynecologic cancer in the All of Us research program

**Poster Presenter:** Allison C. Dona, BS, BA

*Accepted as Poster Session II*

**Abstract Title:** Does living in a food desert impact cancer stage at diagnosis and overall survival among gynecologic cancer patients in Louisiana?

**Poster Presenter:** Tina Nguyen

*Accepted as Poster Session II*

**Abstract Title:** A nationwide comparison of palliative care utilization between common cancer types affecting women: An analysis of the National Cancer Database

**Poster Presenter:** Matthew W. Lee, MD

*Accepted as Poster Session II*

**Abstract Title:** Advanced cervical cancer patients value disease control in addition to overall survival in treatment decision making: A U.S. patient preference study

**Poster Presenter:** Premal H. Thaker, MD

*Accepted as Poster Session II*

**Abstract Title:** Practice patterns in the treatment of small cell carcinoma of the cervix: Analysis of a Canadian multidisciplinary survey

**Poster Presenter:** Kevin Yijun Fan, MD

*Accepted as Poster Session II*

**Abstract Title:** Missing concurrent endometrial carcinoma in patients with endometrial intraepithelial neoplasia: Which is better, directed biopsy versus blinded?

**Poster Presenter:** Kristina A. Butler, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Impact of Medicaid expansion on cervical cancer screening rates: A state-specific difference in difference analysis

**Poster Presenter:** Adrianna M. Bergstein, BA

*Accepted as Poster Session II*

**Abstract Title:** Outcomes in patients with chronic kidney disease undergoing HIPEC for ovarian cancer

**Poster Presenter:** Robert Debernardo, MD

*Accepted as Poster Session II*

**Abstract Title:** Prognostic significance of isolated tumor cells for endometrial cancer

**Poster Presenter:** Monica Neuman, MD

*Accepted as Poster Session II*

**Abstract Title:** eVOLVE-Cervical (GOG-3092/ENGOT-cx19/GEICO133-C): A prospective phase III study of volrustomig versus placebo after definitive chemoradiation in women with high-risk, locally-advanced cervical cancer

**Poster Presenter:** Leslie M. Randall, MD

*Accepted as Poster Session II*

**Abstract Title:** nab-Sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 in a phase II, multicenter, open-label basket trial: PRECISION 1

**Poster Presenter:** Debra L. Richardson, MD

*Accepted as Poster Session II*

**Abstract Title:** Can we rely on our ultrasounds and ourselves? A study on the performance of postmenopausal bleeding assessments and appropriate clinical follow-up

**Poster Presenter:** Angela Nolin, MD

*Accepted as Poster Session II*

**Abstract Title:** nab-Sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer: A phase II, open-label, single-arm, prospective, multi-center study

**Poster Presenter:** Lauren E. Dockery, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** The efficacy and safety of cadonilimab after first anti-PD-1 failure in the treatment of recurrent endometrial and cervical carcinoma: A retrospective, real-world study

**Poster Presenter:** Baoyue Pan, MD

*Accepted as Poster Session II*

**Abstract Title:** Healthcare delivery in patients with endometrial cancer in Colombia: A national cohort study based on administrative claims data

**Poster Presenter:** Giancarlo Buitrago, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Exposure-biomarker analyses for cytokine release syndrome or infusion-related reaction, pain, and cytokine concentrations in serum during treatment with ubamatamab, a MUC16 x CD3 bispecific antibody, in patients with recurrent ovarian cancer

**Poster Presenter:** Priyanka Madia, PhD

*Accepted as Poster Session II*

**Abstract Title:** Impact of body mass index on sentinel lymph node mapping in patients with endometrial cancer: A retrospective cohort study

**Poster Presenter:** Meyha N. Swaroop, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Palliative care referral indications differ according to referral location in patients with cervical cancer

**Poster Presenter:** Jaclyn A. Wall, MD

*Accepted as Poster Session II*

**Abstract Title:** Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer

**Poster Presenter:** Mackenzie W. Sullivan, MD

*Accepted as Poster Session II*

**Abstract Title:** Outcomes of patients with advanced gynecologic cancers enrolled in a

single-center, phase I clinical trial program compared with other advanced solid tumors

**Poster Presenter:** Hadi Erfani, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Disease-free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant therapy

**Poster Presenter:** Linda R. Duska, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Evaluation of a novel screening program for financial toxicity in gynecologic oncology patients at initial consultation

**Poster Presenter:** Nadiha Noor Chelsea, MD

*Accepted as Poster Session II*

**Abstract Title:** The role of adjuvant chemotherapy among patients who undergo preoperative radiation in endometrial cancer: An NCDB study

**Poster Presenter:** Michelle Ertel, MD

*Accepted as Poster Session II*

**Abstract Title:** Environmental exposures and the incidence of vulvar carcinoma in the western Pennsylvania catchment area

**Poster Presenter:** Michelle Ertel, MD

*Accepted as Poster Session II*

**Abstract Title:** Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer

**Poster Presenter:** Whitney S. Graybill, MD, MS, FACOG

*Accepted as Poster Session II*

**Abstract Title:** A fully next-generation sequencing-based method of classifying molecular subtypes of endometrial cancer retains prognostic value and highlights racial

disparities in disease-specific survival

**Poster Presenter:** Mark C. Valentine, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Barriers to HPV vaccination in patients 27-45 years of age among OB/GYN providers and trainees

**Poster Presenter:** Simrit Warring, MD

*Accepted as Poster Session II*

**Abstract Title:** Ovarian cancer survival outcomes of debulking surgery in the hyperthermic intraperitoneal chemotherapy era

**Poster Presenter:** Sarah G. Bell, MD

*Accepted as Poster Session II*

**Abstract Title:** Preliminary results from a phase II clinical trial assessing the safety and efficacy of pembrolizumab in the treatment of high-grade cervical intraepithelial neoplasia

**Poster Presenter:** Maria Garcia Jimenez, MD, MHS

*Accepted as Poster Session II*

**Abstract Title:** Bankruptcy incidence rates among Massachusetts cancer patients are highest among those with cervical and uterine cancers

**Poster Presenter:** Katharine M. Esselen, MD, MBA

*Accepted as Poster Session II*

**Abstract Title:** Gestational trophoblastic disease/neoplasm: A tertiary referral institution experience with treatment and outcomes

**Poster Presenter:** Aaron M. Praiss, MD

*Accepted as Poster Session II*

**Abstract Title:** Gynecologic oncologist at cesarean hysterectomy for placenta accreta

spectrum in the United States: Surgeon specialty-specific assessment

**Poster Presenter:** Andrew Vallejo, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer

**Poster Presenter:** Yunzi Cao, MA

*Accepted as Poster Session II*

**Abstract Title:** Occult endometrial cancer in atypical endometrial hyperplasia: Assessment of clinico-pathological characteristics and oncologic outcomes

**Poster Presenter:** Hiroshi Yoshida, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Healthy days at home after surgery for ovarian cancer: A patient-centered outcome in older adults

**Poster Presenter:** Stephanie Cham, MD

*Accepted as Poster Session II*

**Abstract Title:** AFT-50 EndoMAP: A phase Ib/II, multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer

**Poster Presenter:** Evelyn Cantillo, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Olanzapine versus neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting: A phase III, randomized controlled trial in patients with gynecologic malignancies receiving carboplatin and paclitaxel every three weeks

**Poster Presenter:** Shitanshu Uppal, MD, MBA

*Accepted as Poster Session II*



**Abstract Title:** Disparity in vulvar cancer survival between rural, urban, and metropolitan residence: A National Cancer Database analysis 2012-2019

**Poster Presenter:** Morgan F. Gruner, MD

*Accepted as Poster Session II*

**Abstract Title:** Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare

**Poster Presenter:** Anne Knisely, MD

*Accepted as Poster Session II*

**Abstract Title:** Pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors: A multicenter, single-arm, phase 1b/2 trial (POST-PARPi Trial)

**Poster Presenter:** Chunyan Lan, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Human papillomavirus prevalence and genotype distribution and prognostic factors of vaginal cancer

**Poster Presenter:** Hsiu-Jung Tung, MD

*Accepted as Poster Session II*

**Abstract Title:** Beyond grades: Factors shaping academic career trajectory in gynecologic oncology fellowship applicants

**Poster Presenter:** Emily M. Hinchcliff, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Time toxicity associated with immunotherapy-related adverse events in cervical and endometrial cancer patients

**Poster Presenter:** Julia Chalif, MD

*Accepted as Poster Session II*

**Abstract Title:** Use of ChatGPT for management recommendations in advanced ovarian cancer

**Poster Presenter:** Lindsey Finch

*Accepted as Poster Session II*

**Abstract Title:** Disparities in access to gynecologic oncology care: A SEER-Medicare study

**Poster Presenter:** Clare Cutri-French, MD

*Accepted as Poster Session II*

**Abstract Title:** Patterns in maintenance therapy use in advanced ovarian cancer patients: Real-world data analysis

**Poster Presenter:** Sarah E. Taylor, MD

*Accepted as Poster Session II*

**Abstract Title:** PARP inhibitors and maintenance treatment decision-making in advanced ovarian cancer: Patient and clinician perspectives

**Poster Presenter:** Ashley Haggerty, MD, MSCE

*Accepted as Poster Session II*

**Abstract Title:** Comparison of parental leave policies available to gynecologic oncology fellows in the United States

**Poster Presenter:** Kaylee Underkofler, MD

*Accepted as Poster Session II*

**Abstract Title:** Trends in sentinel lymph node evaluation for vulvar melanoma over time: A national cancer database analysis

**Poster Presenter:** Hadley Reid, MD, MHS

*Accepted as Poster Session II*

**Abstract Title:** Phase I clinical trial of autologous T cells bearing fully-humanized

chimeric antigen receptors targeting mesothelin with both intravenous administration and local delivery with or without lymphodepletion in mesothelin-expressing cancers including ovarian

**Poster Presenter:** Janos L. Tanyi, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** A phase II study in newly-diagnosed, stage III/IV epithelial ovarian cancer evaluating carboplatin/paclitaxel/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by olaparib/pembrolizumab maintenance

**Poster Presenter:** Kaitlyn Kincaid, MD

*Accepted as Poster Session II*

**Abstract Title:** Single-arm, phase II study of carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy with advanced-stage ovarian, fallopian tube or primary peritoneal cancer who are folate receptor alpha positive

**Poster Presenter:** Peter W. Ketch, MD

*Accepted as Poster Session II*

**Abstract Title:** Infiltrative versus expansile invasion: Clinical correlates in mucinous ovarian carcinoma

**Poster Presenter:** Savannah Barkdull, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Long-term survival and prognostic factors in juvenile granulosa cell tumor of ovary

**Poster Presenter:** Yanfang Y.F. Li, MD

*Accepted as Poster Session II*

**Abstract Title:** The implementation of an electronic symptom management system to monitor post-operative pain in gynecologic oncology surgery patients: A multi-center

evaluation

**Poster Presenter:** Leslie Bradford, MD

*Accepted as Poster Session II*

**Abstract Title:** The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multi-center evaluation

**Poster Presenter:** Linh H. Nguyen, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Maximizing effectiveness: Chemotherapy response score and homologous recombination deficiency strategies

**Poster Presenter:** Roni Nitecki, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** The role of ctDNA in the management of vulvar carcinoma with radiation therapy: A preliminary report

**Poster Presenter:** Gabriella Wernicke, MD

*Accepted as Poster Session II*

**Abstract Title:** Ovarian cancer biomarker testing over time in the era of PARP inhibitors

**Poster Presenter:** Joseph A. Dottino, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Patient-reported outcomes in sexual health of cervical cancer survivors after definitive chemoradiation and MRI-guided brachytherapy

**Poster Presenter:** Jennifer Croke, MD, MHPE, FRCPC

*Accepted as Poster Session II*

**Abstract Title:** The association of patient disease characteristics with time to next treatment in the real-world setting of niraparib maintenance: The PREDICT study

**Poster Presenter:** Dana M. Chase, MD

*Accepted as Poster Session II*

**Abstract Title:** Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study

**Poster Presenter:** Zoltan Novak, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?

**Poster Presenter:** Linda R. Duska, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Stage IC, grade one endometrioid adenocarcinoma of the ovary: Assessment of postoperative chemotherapy de-escalation

**Poster Presenter:** Sabrina M. Woll, BA

*Accepted as Poster Session II*

**Abstract Title:** A phase I/IIa, dose-escalation, safety, and preliminary-efficacy study of the RKP00156 vaginal tablet among healthy women and patients with cervical intraepithelial neoplasia two

**Poster Presenter:** Hyun-Woong Cho, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Coping with cancer: An exploration of patient temperament, intrinsic motivation, and personal epistemology as clues to preferred modes of coping and prognostic communication

**Poster Presenter:** Rachel Cerone, MD

*Accepted as Poster Session II*

**Abstract Title:** Addressing sexual health in the care of patients with hereditary breast and ovarian cancer and Lynch syndrome: Patient perspectives

**Poster Presenter:** Jesse T. Brewer, BA

*Accepted as Poster Session II*

**Abstract Title:** Predictors for PARP inhibitor hematologic toxicity in ovarian cancer: Are patients with chemotherapy-induced toxicity at an increased risk?

**Poster Presenter:** Lina Salman, MD, MSc

*Accepted as Poster Session II*

**Abstract Title:** Patterns of adjuvant therapy for endometrial cancer with sentinel lymph node biopsy

**Poster Presenter:** Alice J. Darling, MD

*Accepted as Poster Session II*

**Abstract Title:** A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs. pembrolizumab plus lenvatinib in patients with previously treated mismatch repair-proficient advanced endometrial cancer

**Poster Presenter:** Eugenia Girda, MD, FACOG

*Accepted as Poster Session II*

**Abstract Title:** Assessing adverse pregnancy outcomes and fetal malformations in cancer diagnosed during pregnancy

**Poster Presenter:** Yung-Taek Ouh, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Themes, perspectives, and educational quality of content related to #PapSmears on TikTok and YouTube

**Poster Presenter:** Matthew W. Lee, MD

*Accepted as Poster Session II*

**Abstract Title:** Trends in reimbursement for minimally-invasive gynecologic surgery

**Poster Presenter:** Sarah E. Podwika, MD

*Accepted as Poster Session II*

**Abstract Title:** Medical decision-making from the perspective of the gynecologic oncology patient

**Poster Presenter:** Anna C. Gonzalez, MD

*Accepted as Poster Session II*

**Abstract Title:** Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

**Poster Presenter:** Kimberly Levinson, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Universal distress thermometer screening by a social worker among gynecologic oncology patients improves the rate of distress screening

**Poster Presenter:** Y. Stefanie Chen, MD

*Accepted as Poster Session II*

**Abstract Title:** A phase Ib/II, single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma

**Poster Presenter:** Peter W. Ketch, MD

*Accepted as Poster Session II*

**Abstract Title:** The role of preoperative, sit-to-stand assessment in robotic hysterectomy surgical outcomes

**Poster Presenter:** Samantha Leite, MD

*Accepted as Poster Session II*

**Abstract Title:** The effects of lumbar sympathetic ganglion block therapy on secondary

lower limb lymphedema in patients with gynecological cancer surgery

**Poster Presenter:** Yang Sun, MD

*Accepted as Poster Session II*

**Abstract Title:** Examining health-related quality-of-life outcomes in older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: results from the PRIMA/ENGOT-OV26/GOG-3012

Trial

**Poster Presenter:** Bhavana Pothuri, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Comparison of 2009 FIGO staging to 2023 FIGO staging system in stage I endometrial cancer

**Poster Presenter:** Alex E. Rosenthal, MD, ScM

*Accepted as Poster Session II*

**Abstract Title:** Chronic immune-related adverse events following immunotherapy administration in a gynecologic cancer patient population

**Poster Presenter:** Julia Chalif, MD

*Accepted as Poster Session II*

**Abstract Title:** Progesterone management of early-stage endometrial cancer/complex atypical hyperplasia and association of clinical and TCGA markers to response

**Poster Presenter:** Aparna Kailasam, MD, MBA

*Accepted as Poster Session II*

**Abstract Title:** Estimating the population-level impact of a platinum chemotherapy shortage on patients with gynecologic cancers in the United States: Cost-effectiveness of investing in the supply chain

**Poster Presenter:** Benjamin B. Albright, MD, MS

*Accepted as Poster Session II*



**Abstract Title:** Evaluation of the Khorana score and association with venous thromboembolism incidence among patients with uterine cancer: Implications for patient care

**Poster Presenter:** Alyssa Kretz, MPH

*Accepted as Poster Session II*

**Abstract Title:** Phase II basket study of disitamab vedotin in patients with previously-treated, locally-advanced, unresectable or metastatic solid tumors that express HER2: Ovarian and endometrial cancer cohorts (DV-005; Trial in Progress)

**Poster Presenter:** Joyce F. Liu, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Progression free and overall survival of sequential platinum, taxane, and bevacizumab followed by immuotherapy may be equivalent to concurrent chemotherapy and immunotherapy in patients with recurrent or metastatic cervical cancer

**Poster Presenter:** Michael M. Frumovitz, MD, MPH, MS

*Accepted as Poster Session II*

**Abstract Title:** A phase II, open-label, multi-center, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically-selected advanced or metastatic solid tumors (ARTIST)

**Poster Presenter:** Carol Aghajanian, MD

*Accepted as Poster Session II*

**Abstract Title:** Molecular testing by gynecologic oncologists versus medical oncologists: Is there a difference?

**Poster Presenter:** Martins Ayoola, MD

*Accepted as Poster Session II*

**Abstract Title:** Safety and tolerability of CRX100, an NKT cell therapy combined with

tumor-specific oncolytic vaccinia virus among patients with recurrent, platinum-resistant ovarian cancer

**Poster Presenter:** Oliver Dorigo, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** In the era of the HPV vaccine, what are the current HPV subtypes contributing to high-grade cervical dysplasia, adenocarcinoma in situ and early cervical cancer?

**Poster Presenter:** Allan L. Covens, MD, FRCSC

*Accepted as Poster Session II*

**Abstract Title:** The doc versus the bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology

**Poster Presenter:** Benjamin B. Albright, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Revisiting the benefit of radiosensitizing chemotherapy for older patients with locally-advanced vulvar cancer receiving definitive radiotherapy

**Poster Presenter:** Clare Cutri-French, MD

*Accepted as Poster Session II*

**Abstract Title:** Gynecologic oncology providers' perspectives on discussions around sexual health and function of patients

**Poster Presenter:** Naaman Mehta, MD

*Accepted as Poster Session II*

**Abstract Title:** Real world data of anlotinib for gynecological tumors with liver metastases in China

**Poster Presenter:** Xiaoxian Xu, MD

*Accepted as Poster Session II*

**Abstract Title:** Platinum-free interval predicts overall survival in uterine carcinosarcomas

**Poster Presenter:** William Vintzileos, MD

*Accepted as Poster Session II*

**Abstract Title:** Financial toxicity associated with obtaining childcare while undergoing therapy for gynecologic malignancies.

**Poster Presenter:** Courtney J. Riedinger, MD

*Accepted as Poster Session II*

**Abstract Title:** Multi-dimensional measurements of long-term quality of life and recovery patterns of cervical cancer patients after treatment

**Poster Presenter:** Xin Wu, MD

*Accepted as Poster Session II*

**Abstract Title:** Overshooting the mark: Readability of online patient resources for postmenopausal bleeding as a symptom of endometrial cancer

**Poster Presenter:** Mona Saleh, MD

*Accepted as Poster Session II*

**Abstract Title:** Development of an artificial intelligence-based algorithm for evaluation of patients' symptoms and mental status during chemotherapy using heart rate variability

**Poster Presenter:** Ken Yamaguchi, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Risk of CIN II/III with high-risk, HPV-negative, high-grade Pap smear cytology

**Poster Presenter:** Diana Miao, MD

*Accepted as Poster Session II*

**Abstract Title:** COVID-19 pandemic effect on stage of gynecologic cancers at presentation and time to treatment

**Poster Presenter:** Ester Goldfeld, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Economic burden of cervical cancer in Latin America: A real-world study

**Poster Presenter:** Elizabeth A. Szamreta, PhD, MPH

*Accepted as Poster Session II*

**Abstract Title:** The role of adjuvant radiation in stage II-III endometrial stromal sarcoma

**Poster Presenter:** Megan E. Lander, MD

*Accepted as Poster Session II*

**Abstract Title:** Three-dimensional transvaginal ultrasonography: New resource in preoperative staging in endometrial carcinoma

**Poster Presenter:** Marco Noventa, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Neighborhood poverty affects racial disparity in outcomes for patients with endometrial cancer in Washington, D.C.

**Poster Presenter:** Elizabeth Torrez, BS

*Accepted as Poster Session II*

**Abstract Title:** How long is hCG monitoring required after normalization following evacuation of a complete hydatidiform mole? A national retrospective population study

**Poster Presenter:** Lina Salman, MD, MSc

*Accepted as Poster Session II*

**Abstract Title:** The role of rurality, travel time, and community socioeconomics in patterns of adjuvant therapy receipt among endometrial cancer patients

**Poster Presenter:** Victoria M. Petermann, PhD, BSN, RN

*Accepted as Poster Session II*

**Abstract Title:** Monocyte-to-lymphocyte ratio is an effective biomarker for cervical cancer: An nationwide observational study

**Poster Presenter:** Haijuan Yu

*Accepted as Poster Session II*

**Abstract Title:** Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure

**Poster Presenter:** Karlijn K. Cornel, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Correlation between ctDNA and imaging dynamics in gynecologic malignancies

**Poster Presenter:** Gabriella Wernicke, MD

*Accepted as Poster Session II*

**Abstract Title:** The FDA/EMA-approved medicine deferiprone targets outcome-determining protein hydroxylations: Time- and dose-dependent, differential responses of the genes that encode four classes of hydroxylation-requiring proteins in ARK1-USC, the uterine serous carcin

**Poster Presenter:** Hartmut M. Hanauske-Abel, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Neoadjuvant tislelizumab plus chemotherapy in patients with advanced ovarian cancer: A prospective, single-arm, phase II study

**Poster Presenter:** Jinhua Zhou, MD

*Accepted as Poster Session II*

**Abstract Title:** Port-site metastasis following exploratory laparoscopy in patients with stage III-IV ovarian cancer: Incidence, timing, surgical resection, and morbidity

**Poster Presenter:** Orazio De Tommasi, MD

*Accepted as Poster Session II*

**Abstract Title:** Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015-2021

**Poster Presenter:** Sharonne Holtzman, MD

*Accepted as Poster Session II*

**Abstract Title:** Chemotherapy followed by interval cytoreductive surgery: The most prevalent approach in the upfront treatment of patients with advanced-stage epithelial ovarian cancer in the United States

**Poster Presenter:** Alexandra Bercow, MD

*Accepted as Poster Session II*

**Abstract Title:** Analysis of gender bias in Yelp reviews for gynecologic oncology practices and physicians across the United States

**Poster Presenter:** Malavika Kesavan, MS, MD

*Accepted as Poster Session II*

**Abstract Title:** Impact of the 2023 FIGO staging on a high-risk endometrial cancer cohort

**Poster Presenter:** Arielle Katcher, MD

*Accepted as Poster Session II*

**Abstract Title:** Assessment of endocrine toxicities in gynecologic oncology patients receiving immunotherapy

**Poster Presenter:** Anna C. Gonzalez, MD

*Accepted as Poster Session II*

**Abstract Title:** Oncologic outcomes and adverse events with immunotherapy treatment in frail patients with gynecologic cancers

**Poster Presenter:** Molly A. Morton, MD

*Accepted as Poster Session II*

**Abstract Title:** As seen on TikTok: Using a popular video platform to assess patient perceptions of HPV infection and cervical cancer screening

**Poster Presenter:** Nayla Labban, MD

*Accepted as Poster Session II*

**Abstract Title:** Immunotherapy: Is it all about timing?

**Poster Presenter:** Anna C. Gonzalez, MD

*Accepted as Poster Session II*

**Abstract Title:** Geographic disparities in prescribing patterns of molecularly targeted therapy in advanced and recurrent endometrial cancer

**Poster Presenter:** Grace M. Lee, MD

*Accepted as Poster Session II*

**Abstract Title:** A surgery-based comprehensive treatment improved prognosis in patients with stage IIIC cervical squamous carcinoma: A single center retrospective study

**Poster Presenter:** Hui Wang, MD

*Accepted as Poster Session II*

**Abstract Title:** Randomized, phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses

**Poster Presenter:** Dana M. Roque, MD

*Accepted as Poster Session II*

**Abstract Title:** Impact of geographic region on racial disparities in gynecologic oncology clinical trial enrollment

**Poster Presenter:** Elizabeth A. Tubridy, MD

*Accepted as Poster Session II*

**Abstract Title:** A phase II trial of T cell receptor gene therapy targeting HPV-16 E7 for HPV-associated cancers

**Poster Presenter:** Eugenia Girda, MD, FACOG

*Accepted as Poster Session II*

**Abstract Title:** Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis

**Poster Presenter:** Kyra Hunsberger, BA

*Accepted as Poster Session II*

**Abstract Title:** Beyond carboplatin/paclitaxel: Choice of adjuvant chemotherapy regimen in mucinous ovarian carcinoma

**Poster Presenter:** Savannah Barkdull, MD, MS

*Accepted as Poster Session II*

**Abstract Title:** Suicide rates and cervical cancer patients in the United States: Who is most at risk?

**Poster Presenter:** Kyra Hunsberger, BS

*Accepted as Poster Session II*

**Abstract Title:** Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia patients with progesterone resistance: A retrospective analysis of 61 cases

**Poster Presenter:** Junyu Chen, MD

*Accepted as Poster Session II*

**Abstract Title:** Clinical characteristics of ovarian cancer patients with pathologic complete response after neoadjuvant chemotherapy

**Poster Presenter:** Young Joo Lee, MD



*Accepted as Poster Session II*

**Abstract Title:** Impact of COVID-19 on missed diagnoses of uterine cancer: Who is most affected?

**Poster Presenter:** Nathan Tran

*Accepted as Poster Session II*

**Abstract Title:** Expanding eligibility for hyperthermic intraperitoneal chemotherapy: Consideration for stage IV disease and patients aged 67 and over

**Poster Presenter:** Christianne Persenaire, MD

*Accepted as Poster Session II*

**Abstract Title:** Geospatial insights into social determinants and financial toxicity in patients with gynecological malignancies: A perspective from the ACS data

**Poster Presenter:** Rachael Piver, MD

*Accepted as Poster Session II*

**Abstract Title:** Surveillance of epithelioid trophoblastic tumors and placental site trophoblastic tumors

**Poster Presenter:** Abigail Filicko, MD

*Accepted as Poster Session II*

**Abstract Title:** 90-day readmissions after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer

**Poster Presenter:** Vladislav Kovalik, MD

*Accepted as Poster Session II*

**Abstract Title:** Clinical criteria-triggered checklists appropriately target palliative care consults in hospitalized patients with gynecologic malignancy

**Poster Presenter:** Katelyn Tondo-Steele, DO

*Accepted as Poster Session II*

**Abstract Title:** The decline in complex ovarian cancer procedures performed by surgeons in the United States: 2004-2020

**Poster Presenter:** Syem K. Barakzai, MD

*Accepted as Poster Session II*

**Abstract Title:** Implementation of paramedicine services to avoid emergency room visits

**Poster Presenter:** Mallory Lit, MSN, NP-C, AOCNP-BC

*Accepted as Poster Session II*

**Abstract Title:** Palliative care modules for gynecologic oncologists: Highlighting gaps and boosting knowledge

**Poster Presenter:** Lindsay W. Brubaker, MD

*Accepted as Poster Session II*

**Abstract Title:** Patient perspectives on social needs screening to tackle barriers to cancer care in the gynecologic oncology clinic

**Poster Presenter:** Mahima Krishnamoorthi, BA

*Accepted as Poster Session II*

**Abstract Title:** A phase Ib, multicenter, open-label study of NXP800, a novel Gcn2 kinase activator, in patients with platinum-resistant, *ARID1a*-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)

**Poster Presenter:** Shay Shemesh, MSc

*Accepted as Poster Session II*

**Abstract Title:** Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population

**Poster Presenter:** Thomas F. Chavez, MD

*Accepted as Poster Session II*

**Abstract Title:** Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking

**Poster Presenter:** David Samuel, MD

*Accepted as Poster Session II*

**Abstract Title:** Evaluating the effectiveness of mindfulness alone compared to exercise and mindfulness on fatigue in women with gynaecology cancer: A feasibility study

**Poster Presenter:** Kairen K. Mccloy, BS

*Accepted as Poster Session II*

**Abstract Title:** Impact of obesity class on sentinel node mapping and postoperative complications after robotic surgery for endometrial cancer

**Poster Presenter:** Diletta Fumagalli, MD

*Accepted as Poster Session II*

**Abstract Title:** Association of reviewer experience in discriminating human vs. ChatGPT-written abstracts

**Poster Presenter:** Gabriel Levin, MD

*Accepted as Poster Session II*

**Abstract Title:** Effects of the stress: How poor, self-rated mental health affected cervical cancer screening rates among Hispanic women during the COVID-19 pandemic

**Poster Presenter:** Karen Haney, MD

*Accepted as Poster Session II*

**Abstract Title:** Time interval from biopsy of endometrial intraepithelial neoplasia to surgery and risk for concurrent endometrial carcinoma

**Poster Presenter:** Gabriel Levin, MD

*Accepted as Poster Session II*

**Abstract Title:** Taxane desensitization: An academic institution retrospective review

**Poster Presenter:** Morgan Brown, MD

*Accepted as Poster Session II*

**Abstract Title:** Outcomes of loop electrosurgical excision procedure versus cold knife conization for cervical dysplasia

**Poster Presenter:** Bethany C. Onyirimba

*Accepted as Poster Session II*

**Abstract Title:** The outcome of waiting for radiotherapy in locally-advanced cervical cancer

**Poster Presenter:** David F. Cantu De Leon, MD, PHD

*Accepted as Poster Session II*

**Abstract Title:** REFRAme-O1/ENGOT-OV79/GOG-3086: A phase II/III open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator's choice of chemotherapy in women with relapsed, platinum-resistant epithelial ovarian cancer expressing folate

**Poster Presenter:** R. Wendel Naumann, MD

*Accepted as Poster Session II*

**Abstract Title:** Shades of support: Exploring racial dynamics in a robust gynecologic oncology support group

**Poster Presenter:** Jessa Suhner, MD

*Accepted as Poster Session II*

**Abstract Title:** Evolution of public interest in the human papillomavirus vaccine: Is the message getting across?

**Poster Presenter:** Muhammad Danyal Ahsan, MD

*Accepted as Poster Session II*

**Abstract Title:** Diagnosis-to-treatment interval in cervical cancer: An exploratory analysis of the SEER database

**Poster Presenter:** Mona Saleh, MD

*Accepted as Poster Session II*

**Abstract Title:** Hemostatic efficacy of fibrin sealant patch (TachoSil) in the loop electrosurgical excisional procedure: A prospective randomized controlled study

**Poster Presenter:** Jeong-Yeol Park, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Predicting ovarian cancer without artificial intelligence: What 409,780 patients taught us

**Poster Presenter:** Chelsea E. Stewart, MD, MPH

*Accepted as Poster Session II*

**Abstract Title:** Impact of postmenopausal bleeding duration on uterine cancer prognosis

**Poster Presenter:** Nicolina Mascia, MD

*Accepted as Poster Session II*

**Abstract Title:** Evaluating perceived significance of physical activity in patients with gynecologic cancer: An OBGYN resident survey

**Poster Presenter:** Abigail Jackovic, DO

*Accepted as Poster Session II*

**Abstract Title:** Treatment patterns and outcomes of locally-advanced endometrial cancer patients treated with neoadjuvant radiation

**Poster Presenter:** Daniel Margul, MD, PhD

*Accepted as Poster Session II*

**Abstract Title:** Prolonged total treatment times and associated factors in a cohort of

patients with locally-advanced cervical cancer

**Poster Presenter:** Olga Kovalenko, MD

*Accepted as Poster Session II*

**Abstract Title:** Death at home or hospice varies by race and ethnicity among patients with gynecologic cancer

**Poster Presenter:** Sagar K. Chokshi, DO, MS

*Accepted as Poster Session II*



## Surgical Sessions

**Abstract Title:** Surgical film: Laparoscopic en-bloc pelvic resection with rectosigmoid resection anastomosis for stage IIIB ovarian cancer

**Surgical Session Speaker:** Jacopo J. Ferrari, MD

**Date/Time:** 3/16/2024 between 3:45:00 PM and 5:00:00 PM

Focused Plenary - Focused Plenary III: Farr-Nezhat Surgical Innovation Session

**Abstract Title:** Robotic laterally extended endopelvic resection for recurrent endometrial cancer

**Surgical Session Speaker:** Justin Harold

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VII: Surgical Video: Behind the Double Doors

**Abstract Title:** Metastatic pericardial mass and cardiophrenic lymph node resection in ovarian cancer

**Surgical Session Speaker:** Huaiwu Lu, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VII: Surgical Video: Behind the Double Doors

**Abstract Title:** Open total mesometrial resection

**Surgical Session Speaker:** Kalidindi VVN Raju, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VII: Surgical Video: Behind the Double Doors

**Abstract Title:** Challenges of cytoreduction in porta hepatis

**Surgical Session Speaker:** Kalidindi VVN Raju, MD

**Date/Time:** 3/17/2024 between 3:00:00 PM and 4:00:00 PM

Focused Plenary - Focused Plenary VII: Surgical Video: Behind the Double Doors





## Walking Posters

**Abstract Title:** Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate trastuzumab deruxtecan

**Walking Poster Presenter:** Sara Moufarrij, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 1: Pre-Clinical/Translational Science

**Abstract Title:** Spatial transcriptomics characterizes high-grade serous ovarian cancer and its precursor lesions

**Walking Poster Presenter:** Rahul Krishnan, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 1: Pre-Clinical/Translational Science

**Abstract Title:** Focal adhesion kinase inhibition as maintenance therapy in a homologous recombination repair proficient high-grade serous ovarian cancer murine model

**Walking Poster Presenter:** Breana Hill, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 1: Pre-Clinical/Translational Science

**Abstract Title:** Association of plasma cells with outcomes in ovarian cancer

**Walking Poster Presenter:** Martins Ayoola, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 1: Pre-Clinical/Translational Science

**Abstract Title:** vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter, international prospective case series

**Walking Poster Presenter:** Alexander F. Burnett, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 2: Tips, Tricks, & Surgical Innovations

**Abstract Title:** Postoperative voiding dysfunction by void trial methodology following radical hysterectomy for cervical cancer

**Walking Poster Presenter:** Matt K. Wagar, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 2: Tips, Tricks, & Surgical Innovations

**Abstract Title:** Postoperative complications in gynecologic oncology patients receiving therapeutic anticoagulation

**Walking Poster Presenter:** Hannah McLaughlin, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 2: Tips, Tricks, & Surgical Innovations

**Abstract Title:** Analysis of a promising composite quality measure for management of advanced ovarian cancer: Is there a 'textbook outcome'?

**Walking Poster Presenter:** Giuseppe Caruso, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 2: Tips, Tricks, & Surgical Innovations

**Abstract Title:** The impact of environmental factors and social determinants of health on mismatch repair status in a single-center endometrial cancer cohort

**Walking Poster Presenter:** Alysia Wiener, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 3: Genes, Genetics, Hereditary Cancers

**Abstract Title:** Low-grade endometrial cancer histology at diagnosis does not improve survival in the *TP53* molecular subtype regardless of stage: A large, retrospective cohort validated by the TCGA dataset

**Walking Poster Presenter:** Rosemary N. Senguttuvan, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 3: Genes, Genetics, Hereditary Cancers

**Abstract Title:** Implementation of an interactive digital cancer risk assessment tool in a Medicaid predominant, racially-diverse gynecology clinic in Brooklyn, New York

**Walking Poster Presenter:** Michael Kim, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 3: Genes, Genetics, Hereditary Cancers

**Abstract Title:** Immune checkpoint inhibition for mismatch repair-deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database

**Walking Poster Presenter:** Lindsay Borden, MD

**Date/Time:** 3/17/2024 between 7:30:00 AM and 8:00:00 AM

Walking Poster Session - Walking Poster Group 3: Genes, Genetics, Hereditary Cancers

**Abstract Title:** Association of area deprivation index on outcomes of women with non-metastatic endometrioid endometrial cancer treated at a large urban academic hospital

**Walking Poster Presenter:** Sarah A. Ackroyd, MD, MPH

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 4: Working Together with the Patient at the Center

**Abstract Title:** Immune related adverse events in metastatic/recurrent cervical and vulvar cancer associated with significant survival advantage

**Walking Poster Presenter:** Steven B. Holloway, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 4: Working Together with the Patient at the Center

**Abstract Title:** The over- and under- in treating frail ovarian cancer patients: A qualitative study of patient/caregiver dyads and their multi-disciplinary teams

**Walking Poster Presenter:** Rachel A. Pozzar, PhD, RN

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 4: Working Together with the Patient at the Center

**Abstract Title:** Using a modified SAMANTA score to screen at-risk women seeking bariatric surgery for postmenopausal or abnormal uterine bleeding

**Walking Poster Presenter:** Amelia M. Jernigan, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 4: Working Together with the Patient at the Center

**Abstract Title:** Surveillance visits for ovarian cancer: Is it time to reconsider the pelvic exam?

**Walking Poster Presenter:** Caroline Gellman, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 4: Working Together with the Patient at the Center

**Abstract Title:** Readability in patient information for cervical cancer in NCI comprehensive cancer centers: Addressing cancer-care barriers

**Walking Poster Presenter:** Wafa Khadraoui, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** Caring beyond the cost: Finance-related treatment delays in gynecologic cancer patients receiving treatment with immunotherapy

**Walking Poster Presenter:** Molly A. Morton, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** Survival outcomes according to molecular classification of uterine carcinosarcoma

**Walking Poster Presenter:** Kaitlyn Kincaid, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** The effect of medicaid expansion on the receipt of guideline-concordant care among patients with cervical cancer in the United States: A difference-in-difference analysis of the NCDB

**Walking Poster Presenter:** Andreea Dinicu, MD, MPH

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** Real-world evaluation of VIA/VILI for triage of HPV screen-positive women in a cervical cancer screening program from China

**Walking Poster Presenter:** Sumeng Wang, PhD candidate

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** Post-operative acute pain trajectories in gynecologic cancer patients undergoing hysterectomy

**Walking Poster Presenter:** Jian Zhao, MS, RN, PhD candidate

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 5: Cancer Care Delivery

**Abstract Title:** Implementation of automated social determinants of health screening in gynecologic oncology: A pilot study

**Walking Poster Presenter:** Anna Jo B. Smith, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 6: All-in Access to Clinical Trials

**Abstract Title:** Assessment of readability of gynecologic cancer clinical trials literature at NCI comprehensive cancer centers

**Walking Poster Presenter:** Julia Chalif, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 6: All-in Access to Clinical Trials

**Abstract Title:** Shared telehealth for multidisciplinary gynecologic cancer survivorship (steel magnolias): A hybrid virtual and in-person cancer surveillance program that delivers high quality surveillance care to rural communities

**Walking Poster Presenter:** Amelia M. Jernigan, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 6: All-in Access to Clinical Trials

**Abstract Title:** Group appointments for cancer survivorship equity (GRACE): Evaluating the use of group medical visits in rural and underserved gynecologic cancer survivors

**Walking Poster Presenter:** Ivana Barouhas, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 6: All-in Access to Clinical Trials

**Abstract Title:** Pre-operative diagnosis of endometrial intraepithelial neoplasia and risk of concurrent endometrial cancer: Does tissue sampling technique matter?

**Walking Poster Presenter:** Jenna Zimmerman, MD

**Date/Time:** 3/17/2024 between 8:15:00 AM and 8:45:00 AM

Walking Poster Session - Walking Poster Group 6: All-in Access to Clinical Trials